Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:oxazinane
go back to main search page
Accession:CHEBI:46952 term browser browse the term
Synonyms:related_synonym: oxazinanes


show annotations for term's descendants           Sort by:
 
(S)-timolol (anhydrous) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adrb1 adrenoceptor beta 1 multiple interactions ISO Timolol binds to and results in decreased activity of ADRB1 protein; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] CTD PMID:11436944, PMID:15060759 NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions ISO [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Timolol binds to and results in decreased activity of ADRB2 protein CTD PMID:11436944, PMID:17925438 NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
JBrowse link
G Aoc1 amine oxidase, copper containing 1 multiple interactions EXP Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein] CTD PMID:2860926 NCBI chr 4:78,496,043...78,515,582
Ensembl chr 4:78,496,043...78,515,584
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects response to substance ISO CYP2D6 gene SNP affects the susceptibility to Timolol CTD PMID:19284319, PMID:20925579 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein] CTD PMID:18977218 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:18977218 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Rgs3 regulator of G-protein signaling 3 multiple interactions ISO RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:18977218 NCBI chr 5:78,429,017...78,567,281
Ensembl chr 5:78,428,669...78,567,288
JBrowse link
G Rgs4 regulator of G-protein signaling 4 multiple interactions ISO RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:18977218 NCBI chr13:88,054,817...88,061,108
Ensembl chr13:88,054,817...88,061,108
JBrowse link
3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Top1 DNA topoisomerase I increases activity ISO 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin results in increased activity of TOP1 protein CTD PMID:2164630 NCBI chr 3:156,635,688...156,717,686
Ensembl chr 3:156,642,464...156,717,686
JBrowse link
AH23848 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of AKT1 protein CTD PMID:19407222 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Arrb1 arrestin, beta 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of ARRB1 protein CTD PMID:19407222 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
JBrowse link
G Axin1 axin 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein] CTD PMID:19407222
G Bad BCL2-associated agonist of cell death multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of BAD protein CTD PMID:19407222 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased expression of BAX protein CTD PMID:19407222 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2 protein CTD PMID:19407222 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2L1 protein CTD PMID:19407222 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of CASP3 protein
AH 23848 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]
CTD PMID:19407222, PMID:32115946 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased degradation of CTNNB1 protein CTD PMID:19407222 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions ISO AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein] CTD PMID:20678559, PMID:28571770 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein] CTD PMID:20093341 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein CTD PMID:19407222 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Egr1 early growth response 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of EGR1 protein CTD PMID:19407222 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of FOS protein CTD PMID:19407222 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of GSK3B protein CTD PMID:19407222 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of IL1R1 protein CTD PMID:19407222 NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of JUN protein CTD PMID:19407222 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Lep leptin multiple interactions ISO AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] CTD PMID:28571770 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK1 protein CTD PMID:19407222 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK3 protein CTD PMID:19407222 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MYC protein CTD PMID:19407222 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of NFKB1 protein CTD PMID:19407222 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of NFKBIA protein CTD PMID:19407222 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of PARP1 protein CTD PMID:19407222 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Ptger2 prostaglandin E receptor 2 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein] CTD PMID:19407222 NCBI chr15:19,336,029...19,349,759
Ensembl chr15:19,338,175...19,350,210
JBrowse link
G Ptger4 prostaglandin E receptor 4 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein] CTD PMID:19407222 NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein] CTD PMID:20678559 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of RELA protein CTD PMID:19407222 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of SP1 protein CTD PMID:19407222 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of SRC protein CTD PMID:19407222 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Tcf7 transcription factor 7 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7 protein CTD PMID:19407222 NCBI chr10:37,616,033...37,646,027
Ensembl chr10:37,617,279...37,645,802
JBrowse link
G Tcf7l2 transcription factor 7 like 2 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7L2 protein CTD PMID:19407222 NCBI chr 1:276,686,911...276,730,517
Ensembl chr 1:276,659,542...276,730,514
Ensembl chr 1:276,659,542...276,730,514
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO AH 23848 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] CTD PMID:9298541 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TNFRSF1A protein CTD PMID:19407222 NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
JBrowse link
alectinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alk ALK receptor tyrosine kinase affects response to substance ISO ALK protein affects the susceptibility to alectinib CTD PMID:29458018 NCBI chr 6:22,696,415...23,203,791
Ensembl chr 6:22,696,397...23,203,775
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO alectinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
amorolfine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] CTD PMID:23688403 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO amorolfine inhibits the reaction [Biological Products results in increased expression of CXCL10 mRNA]; amorolfine inhibits the reaction [Biological Products results in increased expression of CXCL10 protein] CTD PMID:24471457 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Il4 interleukin 4 multiple interactions ISO 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; amorolfine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone] CTD PMID:23688403 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO amorolfine results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] CTD PMID:23688403 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO amorolfine inhibits the reaction [Biological Products results in increased phosphorylation of and results in increased activity of STAT1 protein] CTD PMID:24471457 NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
JBrowse link
G Tslp thymic stromal lymphopoietin multiple interactions ISO 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] CTD PMID:23688403 NCBI chr18:25,613,601...25,618,066
Ensembl chr18:25,613,831...25,617,361
JBrowse link
aprepitant term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bad BCL2-associated agonist of cell death multiple interactions
increases expression
ISO Arsenic Trioxide promotes the reaction [Aprepitant results in increased expression of BAD mRNA] CTD PMID:30145367 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO Arsenic Trioxide promotes the reaction [Aprepitant results in increased expression of BAX mRNA] CTD PMID:30145367 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of BCL2 mRNA CTD PMID:30145367 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in increased expression of BID mRNA CTD PMID:30145367 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions
ISO Aprepitant results in decreased expression of BIRC2 mRNA
Arsenic Trioxide promotes the reaction [Aprepitant results in decreased expression of BIRC2 mRNA]
CTD PMID:30145367 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 multiple interactions
decreases expression
ISO Arsenic Trioxide promotes the reaction [Aprepitant results in decreased expression of BIRC3 mRNA] CTD PMID:30145367 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of BIRC5 mRNA CTD PMID:30145367 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions
ISO Aprepitant results in increased activity of CASP3 protein
Aprepitant promotes the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; Arsenic Trioxide promotes the reaction [Aprepitant results in increased activity of CASP3 protein]
CTD PMID:30145367 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in increased expression of CDKN1A mRNA CTD PMID:30145367 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of MCL1 mRNA CTD PMID:30145367 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mmp12 matrix metallopeptidase 12 multiple interactions ISO aprepitant inhibits the reaction [TAC1 protein results in increased expression of MMP12 mRNA] CTD PMID:18441096 NCBI chr 8:5,594,717...5,616,494
Ensembl chr 8:5,606,592...5,616,493
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of MYC mRNA CTD PMID:30145367 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nfkbia NFKB inhibitor alpha decreases phosphorylation
multiple interactions
ISO Aprepitant results in decreased phosphorylation of NFKBIA protein
Arsenic Trioxide promotes the reaction [Aprepitant results in decreased phosphorylation of NFKBIA protein]
CTD PMID:30145367 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Pgr progesterone receptor multiple interactions ISO aprepitant binds to and results in decreased activity of PGR protein CTD PMID:25752796 NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
JBrowse link
G Tac1 tachykinin, precursor 1 multiple interactions ISO aprepitant inhibits the reaction [TAC1 protein results in increased expression of MMP12 mRNA]; aprepitant inhibits the reaction [TAC1 protein results in increased expression of TACR1 mRNA] CTD PMID:18441096 NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
JBrowse link
G Tacr1 tachykinin receptor 1 multiple interactions ISO aprepitant binds to and results in decreased activity of TACR1 protein
aprepitant inhibits the reaction [TAC1 protein results in increased expression of TACR1 mRNA]
CTD PMID:18441096, PMID:20623144, PMID:20718754 NCBI chr 4:113,247,236...113,416,139
Ensembl chr 4:113,247,795...113,414,504
JBrowse link
G Thra thyroid hormone receptor alpha multiple interactions ISO aprepitant binds to and results in decreased activity of THRA protein CTD PMID:25752796 NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
JBrowse link
G Tp73 tumor protein p73 multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in increased expression of TP73 mRNA CTD PMID:30145367 NCBI chr 5:171,355,876...171,415,354
Ensembl chr 5:171,355,876...171,415,354
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of XIAP mRNA CTD PMID:30145367 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
canertinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen results in increased transport of AIFM1 protein] CTD PMID:28123000 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased expression of CCND1 protein] CTD PMID:28123000 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased expression of CDK4 protein] CTD PMID:28123000 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Egf epidermal growth factor multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:18927496 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases phosphorylation
decreases activity
ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
Canertinib inhibits the reaction [Acetaminophen affects the localization of EGFR protein]; Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein]
Canertinib results in decreased phosphorylation of EGFR protein
Canertinib results in decreased activity of EGFR protein; Canertinib results in decreased activity of EGFR protein mutant form
CTD PMID:15956251, PMID:18927496, PMID:21322567, PMID:28123000 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Endog endonuclease G multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen results in increased transport of ENDOG protein] CTD PMID:28123000 NCBI chr 3:8,741,833...8,744,414
Ensembl chr 3:8,741,766...8,744,592
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein] CTD PMID:18927496 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] CTD PMID:18927496 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:18927496 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of RB1 protein] CTD PMID:28123000 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases activity ISO Canertinib results in decreased activity of TGFB1 protein CTD PMID:31652400 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression
decreases secretion
ISO Canertinib results in decreased expression of VEGFA mRNA; Canertinib results in decreased expression of VEGFA protein
Canertinib results in decreased secretion of VEGFA protein
CTD PMID:15956251 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
carfilzomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Afp alpha-fetoprotein multiple interactions EXP carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] CTD PMID:24632418 NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
JBrowse link
G Ar androgen receptor multiple interactions ISO carfilzomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:30818834 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Brca1 BRCA1, DNA repair associated increases response to substance ISO BRCA1 mutant form results in increased susceptibility to carfilzomib CTD PMID:25522274 NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
JBrowse link
G Brd4 bromodomain containing 4 multiple interactions ISO carfilzomib inhibits the reaction [ARV-825 results in increased degradation of BRD4 protein] CTD PMID:26051217 NCBI chr 7:14,222,101...14,303,055
Ensembl chr 7:14,222,101...14,303,055
JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO carfilzomib results in decreased expression of COX8A mRNA CTD PMID:30818834 NCBI chr 1:222,466,575...222,468,896
Ensembl chr 1:222,466,575...222,468,896
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO carfilzomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:30818834 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO carfilzomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] CTD PMID:30818834 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G Esrra estrogen related receptor, alpha multiple interactions ISO carfilzomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; carfilzomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] CTD PMID:30818834 NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO carfilzomib inhibits the reaction [Acetaminophen results in increased activity of GPT protein] CTD PMID:27900802 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions EXP carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] CTD PMID:24632418 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases activity ISO carfilzomib results in increased activity of NFE2L2 protein CTD PMID:30818834 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO carfilzomib inhibits the reaction [Acetaminophen results in increased expression of NOS2 mRNA] CTD PMID:27900802 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Pgr progesterone receptor multiple interactions ISO carfilzomib inhibits the reaction [Promegestone results in increased activity of PGR protein] CTD PMID:30818834 NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO carfilzomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] CTD PMID:30818834 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Prkcsh protein kinase C substrate 80K-H increases response to substance ISO PRKCSH gene mutant form results in increased susceptibility to carfilzomib CTD PMID:21685914 NCBI chr 8:23,014,802...23,026,507
Ensembl chr 8:23,014,956...23,026,503
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO carfilzomib inhibits the reaction [Acetaminophen results in increased expression of PTGS2 mRNA] CTD PMID:27900802 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases activity ISO carfilzomib results in decreased activity of TGFB1 protein CTD PMID:31652400 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions EXP carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of TIMP1 protein] CTD PMID:24632418 NCBI chr  X:1,364,771...1,369,451
Ensembl chr  X:1,364,786...1,369,384
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO carfilzomib inhibits the reaction [Acetaminophen results in increased expression of TNF protein] CTD PMID:27900802 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 increases activity ISO carfilzomib results in increased activity of TP53 protein CTD PMID:30818834 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
dimethomorph term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor multiple interactions ISO dimethomorph inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] CTD PMID:21310686 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Pde4a phosphodiesterase 4A decreases activity ISO dimethomorph results in decreased activity of PDE4A protein CTD PMID:21251949 NCBI chr 8:22,189,533...22,234,036
Ensembl chr 8:22,189,600...22,233,748
JBrowse link
doramapimod term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO BIRB 796 results in increased expression of ABCC2 mRNA CTD PMID:21328587 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Actg2 actin gamma 2, smooth muscle increases expression EXP BIRB 796 results in increased expression of ACTG2 mRNA CTD PMID:24303162 NCBI chr 4:115,215,160...115,239,746
Ensembl chr 4:115,215,060...115,239,723
JBrowse link
G Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide increases expression EXP BIRB 796 results in increased expression of ADH7 mRNA CTD PMID:24303162 NCBI chr 2:243,500,540...243,516,865
Ensembl chr 2:243,502,073...243,516,532
JBrowse link
G Ahsg alpha-2-HS-glycoprotein decreases expression ISO BIRB 796 results in decreased expression of AHSG mRNA CTD PMID:21328587 NCBI chr11:81,711,269...81,717,594 JBrowse link
G Ak5 adenylate kinase 5 increases expression EXP BIRB 796 results in increased expression of AK5 mRNA CTD PMID:24303162 NCBI chr 2:257,671,772...257,864,385
Ensembl chr 2:257,671,772...257,864,385
JBrowse link
G Akr1b7 aldo-keto reductase family 1, member B7 increases expression ISO BIRB 796 results in increased expression of AKR1B7 mRNA CTD PMID:21328587 NCBI chr 4:61,850,256...61,879,733
Ensembl chr 4:61,850,348...61,862,526
JBrowse link
G Apoa4 apolipoprotein A4 decreases expression ISO BIRB 796 results in decreased expression of APOA4 mRNA CTD PMID:21328587 NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
JBrowse link
G C1qa complement C1q A chain decreases expression ISO BIRB 796 results in decreased expression of C1QA mRNA CTD PMID:21328587 NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
JBrowse link
G C1qb complement C1q B chain decreases expression ISO BIRB 796 results in decreased expression of C1QB mRNA CTD PMID:21328587 NCBI chr 5:155,246,444...155,251,995
Ensembl chr 5:155,246,447...155,252,003
JBrowse link
G Ca3 carbonic anhydrase 3 decreases expression ISO BIRB 796 results in decreased expression of CAR3 mRNA CTD PMID:21328587 NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
JBrowse link
G Cd5l Cd5 molecule-like decreases expression ISO BIRB 796 results in decreased expression of CD5L mRNA CTD PMID:21328587 NCBI chr 2:186,685,104...186,696,117
Ensembl chr 2:186,685,104...186,696,117
JBrowse link
G Cd74 CD74 molecule decreases expression ISO BIRB 796 results in decreased expression of CD74 mRNA CTD PMID:21328587 NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
JBrowse link
G Ceacam1 CEA cell adhesion molecule 1 decreases expression EXP BIRB 796 results in decreased expression of CEACAM1 mRNA CTD PMID:24303162 NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
JBrowse link
G Ces3a carboxylesterase 3a increases expression ISO BIRB 796 results in increased expression of CES3 mRNA CTD PMID:21328587 NCBI chr19:37,070,705...37,079,411 JBrowse link
G Clec1b C-type lectin domain family 1, member B decreases expression ISO BIRB 796 results in decreased expression of CLEC1B mRNA CTD PMID:21328587 NCBI chr 4:163,161,941...163,170,470
Ensembl chr 4:163,162,211...163,170,466
JBrowse link
G Ctss cathepsin S decreases expression ISO BIRB 796 results in decreased expression of CTSS mRNA CTD PMID:21328587 NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions ISO BIRB 796 inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] CTD PMID:14997032 NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases secretion ISO BIRB 796 results in decreased secretion of CXCL10 protein CTD PMID:17996064 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO BIRB 796 inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] CTD PMID:14997032 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Cxcr1 C-X-C motif chemokine receptor 1 multiple interactions ISO BIRB 796 inhibits the reaction [Lipopolysaccharides results in decreased expression of CXCR1 protein] CTD PMID:14997032 NCBI chr 9:81,466,430...81,469,299
Ensembl chr 9:81,466,332...81,469,274
JBrowse link
G Cxcr2 C-X-C motif chemokine receptor 2 multiple interactions ISO BIRB 796 inhibits the reaction [Lipopolysaccharides results in decreased expression of CXCR2 protein] CTD PMID:14997032 NCBI chr 9:81,427,275...81,435,065
Ensembl chr 9:81,427,730...81,434,102
JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 increases expression ISO BIRB 796 results in increased expression of CYP2A5 mRNA CTD PMID:21328587 NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyss cystatin S decreases expression EXP BIRB 796 results in decreased expression of CYSS mRNA CTD PMID:24303162 NCBI chr 3:144,427,430...144,431,768
Ensembl chr 3:144,427,207...144,431,806
JBrowse link
G Egr1 early growth response 1 increases expression ISO BIRB 796 results in increased expression of EGR1 mRNA CTD PMID:21328587 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Fcgr2b Fc fragment of IgG receptor IIb decreases expression ISO BIRB 796 results in decreased expression of FCGR2B mRNA CTD PMID:21328587 NCBI chr13:89,329,298...89,343,916
Ensembl chr13:89,327,794...89,433,815
JBrowse link
G Fgf8 fibroblast growth factor 8 decreases expression EXP BIRB 796 results in decreased expression of FGF8 mRNA CTD PMID:24303162 NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
JBrowse link
G G6pc glucose-6-phosphatase, catalytic subunit decreases expression ISO BIRB 796 results in decreased expression of G6PC mRNA CTD PMID:21328587 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression ISO BIRB 796 results in increased expression of GCLC mRNA CTD PMID:21328587 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gpx2 glutathione peroxidase 2 increases expression ISO BIRB 796 results in increased expression of GPX2 mRNA CTD PMID:21328587 NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
JBrowse link
G Grm8 glutamate metabotropic receptor 8 increases expression EXP BIRB 796 results in increased expression of GRM8 mRNA CTD PMID:24303162 NCBI chr 4:54,474,344...55,409,526
Ensembl chr 4:54,474,136...55,407,922
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression ISO BIRB 796 results in increased expression of GSTA2 mRNA CTD PMID:21328587 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gsta5 glutathione S-transferase alpha 5 increases expression ISO BIRB 796 results in increased expression of GSTA1 mRNA CTD PMID:21328587 NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179
JBrowse link
G Gsta6 glutathione S-transferase alpha 6 increases expression ISO BIRB 796 results in increased expression of GSTA2 mRNA CTD PMID:21328587 NCBI chr 9:27,475,273...27,533,939
Ensembl chr 9:27,475,273...27,511,176
JBrowse link
G Gstm2 glutathione S-transferase mu 2 increases expression ISO BIRB 796 results in increased expression of GSTM2 mRNA CTD PMID:21328587 NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 increases expression ISO BIRB 796 results in increased expression of GSTM3 mRNA CTD PMID:21328587 NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
JBrowse link
G Hp haptoglobin decreases expression ISO BIRB 796 results in decreased expression of HP mRNA CTD PMID:21328587 NCBI chr19:42,096,255...42,100,805
Ensembl chr19:42,097,995...42,100,804
JBrowse link
G Hpd 4-hydroxyphenylpyruvate dioxygenase decreases expression EXP BIRB 796 results in decreased expression of HPD mRNA CTD PMID:24303162 NCBI chr12:38,828,606...38,839,956
Ensembl chr12:38,828,444...38,839,969
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO BIRB 796 inhibits the reaction [Dinitrofluorobenzene results in increased expression of ICAM1 protein] CTD PMID:19427879 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 decreases expression EXP BIRB 796 results in decreased expression of KCNK1 mRNA CTD PMID:24303162 NCBI chr19:58,823,836...58,862,926
Ensembl chr19:58,823,814...58,862,926
JBrowse link
G Lmod1 leiomodin 1 increases expression EXP BIRB 796 results in increased expression of LMOD1 mRNA CTD PMID:24303162 NCBI chr13:52,147,099...52,189,835
Ensembl chr13:52,147,555...52,190,228
JBrowse link
G Meig1 meiosis/spermiogenesis associated 1 increases expression ISO BIRB 796 results in increased expression of MEIG1 mRNA CTD PMID:21328587 NCBI chr17:78,813,656...78,829,411
Ensembl chr17:78,817,529...78,829,411
JBrowse link
G Mt1 metallothionein 1 increases expression ISO BIRB 796 results in increased expression of MT1 mRNA CTD PMID:21328587 NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
JBrowse link
G Mybpc1 myosin binding protein C1 decreases expression EXP BIRB 796 results in decreased expression of MYBPC1 mRNA CTD PMID:24303162 NCBI chr 7:29,086,159...29,171,909
Ensembl chr 7:29,086,156...29,171,783
JBrowse link
G Myh11 myosin heavy chain 11 increases expression EXP BIRB 796 results in increased expression of MYH11 mRNA CTD PMID:24303162 NCBI chr10:764,421...859,184
Ensembl chr10:764,421...859,184
JBrowse link
G Myh3 myosin heavy chain 3 increases expression EXP BIRB 796 results in increased expression of MYH3 mRNA CTD PMID:24303162 NCBI chr10:53,621,375...53,645,194
Ensembl chr10:53,621,375...53,645,194
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO BIRB 796 results in increased expression of NQO1 mRNA CTD PMID:21328587 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Olr59 olfactory receptor 59 increases expression EXP BIRB 796 results in increased expression of OLR59 mRNA CTD PMID:24303162 NCBI chr 1:167,906,030...167,940,688
Ensembl chr 1:167,906,061...167,911,961
JBrowse link
G Otog otogelin decreases expression EXP BIRB 796 results in decreased expression of OTOG mRNA CTD PMID:24303162 NCBI chr 1:102,258,124...102,327,201
Ensembl chr 1:102,258,124...102,327,201
JBrowse link
G Pfn2 profilin 2 increases expression ISO BIRB 796 results in increased expression of PFN2 mRNA CTD PMID:21328587 NCBI chr 2:147,953,858...147,959,692
Ensembl chr 2:147,955,196...148,050,438
JBrowse link
G Pon1 paraoxonase 1 decreases expression EXP BIRB 796 results in decreased expression of PON1 mRNA CTD PMID:24303162 NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression ISO BIRB 796 results in increased expression of PPARG mRNA CTD PMID:21328587 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Prm2 protamine 2 increases expression ISO BIRB 796 results in increased expression of PRM2 mRNA CTD PMID:21328587 NCBI chr10:4,950,484...4,950,920
Ensembl chr10:4,950,484...4,950,920
JBrowse link
G Rgs4 regulator of G-protein signaling 4 increases expression EXP BIRB 796 results in increased expression of RGS4 mRNA CTD PMID:24303162 NCBI chr13:88,054,817...88,061,108
Ensembl chr13:88,054,817...88,061,108
JBrowse link
G RT1-Bb RT1 class II, locus Bb decreases expression ISO BIRB 796 results in decreased expression of H2-AB1 mRNA CTD PMID:21328587 NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
JBrowse link
G Slc7a11 solute carrier family 7 member 11 increases expression ISO BIRB 796 results in increased expression of SLC7A11 mRNA CTD PMID:21328587 NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
JBrowse link
G Spock2 SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2 decreases expression EXP BIRB 796 results in decreased expression of SPOCK2 mRNA CTD PMID:24303162 NCBI chr20:29,654,926...29,679,927
Ensembl chr20:29,655,226...29,677,926
JBrowse link
G Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 decreases expression ISO BIRB 796 results in decreased expression of SPSB1 mRNA CTD PMID:21328587 NCBI chr 5:166,913,734...166,978,534
Ensembl chr 5:166,913,735...166,926,636
JBrowse link
G Srxn1 sulfiredoxin 1 increases expression ISO BIRB 796 results in increased expression of SRXN1 mRNA CTD PMID:21328587 NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
JBrowse link
G Stmn2 stathmin 2 increases expression EXP BIRB 796 results in increased expression of STMN2 mRNA CTD PMID:24303162 NCBI chr 2:95,424,251...95,471,900
Ensembl chr 2:95,424,251...95,472,115
JBrowse link
G Vsig4 V-set and immunoglobulin domain containing 4 decreases expression ISO BIRB 796 results in decreased expression of VSIG4 mRNA CTD PMID:21328587 NCBI chr  X:65,370,851...65,400,298
Ensembl chr  X:65,370,851...65,400,298
JBrowse link
G Zfp324 zinc finger protein 324 increases expression ISO BIRB 796 results in increased expression of ZFP324 mRNA CTD PMID:21328587 NCBI chr 1:65,604,342...65,612,196
Ensembl chr 1:65,606,520...65,611,815
JBrowse link
doxapram term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crh corticotropin releasing hormone increases expression EXP Doxapram results in increased expression of CRH mRNA; Doxapram results in increased expression of CRH protein CTD PMID:16269353 NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
JBrowse link
G Prl prolactin increases expression ISO Doxapram results in increased expression of PRL protein CTD PMID:15741000 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
epoxomicin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions
affects localization
ISO epoxomicin inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]
epoxomicin affects the localization of AHR protein
CTD PMID:17445780 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of ATF4 protein]] CTD PMID:25639565 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of BAX protein]] CTD PMID:25639565 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of BCL2 protein]] CTD PMID:25639565 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression
multiple interactions
ISO epoxomicin results in increased expression of BIRC5 protein
epoxomicin inhibits the reaction [Aspirin results in decreased expression of BIRC5 protein]
CTD PMID:17510429, PMID:18483385 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Casp3 caspase 3 multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:25639565 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO epoxomicin inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression ISO epoxomicin affects the expression of CFLAR protein alternative form CTD PMID:17510429 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Dao D-amino-acid oxidase affects localization ISO epoxomicin affects the localization of DAO protein CTD PMID:28451739 NCBI chr12:48,353,691...48,373,647
Ensembl chr12:48,354,196...48,365,784
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of EIF2AK3 protein]] CTD PMID:25639565 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of EIF2S1 protein]] CTD PMID:25639565 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of ERN1 protein]] CTD PMID:25639565 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions
increases expression
ISO epoxomicin inhibits the reaction [scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; epoxomicin inhibits the reaction [scutellarin results in decreased expression of HIF1A protein]
epoxomicin results in increased expression of HIF1A protein
CTD PMID:25192544 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Nfe2l1 nuclear factor, erythroid 2-like 1 multiple interactions ISO epoxomicin results in increased expression of and affects the localization of NFE2L1 protein; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMA2 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMC4 mRNA] CTD PMID:27345029 NCBI chr10:84,686,762...84,699,313
Ensembl chr10:84,682,460...84,698,886
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases expression ISO epoxomicin results in increased expression of NFE2L2 protein CTD PMID:22558124 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Optn optineurin increases expression ISO
EXP
epoxomicin results in increased expression of OPTN protein CTD PMID:21059646 NCBI chr17:77,167,700...77,218,374
Ensembl chr17:77,167,740...77,218,389
JBrowse link
G Pacrg parkin coregulated decreases expression EXP
ISO
epoxomicin results in decreased expression of PACRG mRNA CTD PMID:18586549 NCBI chr 1:50,070,273...50,491,323 JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO quinoline-val-asp(OMe)-CH2-OPH inhibits the reaction [epoxomicin results in increased cleavage of PARP1 protein] CTD PMID:20153345 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pdyn prodynorphin multiple interactions
decreases expression
ISO
EXP
epoxomicin inhibits the reaction [Potassium results in increased secretion of PDYN protein alternative form]; epoxomicin results in decreased expression of and results in decreased secretion of PDYN protein alternative form
epoxomicin results in decreased expression of PDYN protein alternative form
CTD PMID:17670969 NCBI chr 3:122,194,327...122,206,671
Ensembl chr 3:122,194,329...122,206,671
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO epoxomicin inhibits the reaction [resveratrol results in decreased expression of PPARG protein]; epoxomicin inhibits the reaction [rosiglitazone results in decreased expression of PPARG protein] CTD PMID:18555852 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase decreases expression
multiple interactions
ISO
EXP
epoxomicin results in decreased expression of PRKN mRNA
epoxomicin inhibits the reaction [PRKN protein results in decreased susceptibility to Ceramides]
CTD PMID:12588799, PMID:18586549 NCBI chr 1:48,880,015...50,069,998 JBrowse link
G Psma2 proteasome 20S subunit alpha 2 multiple interactions
increases expression
ISO NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMA2 mRNA] CTD PMID:27345029 NCBI chr17:53,091,937...53,102,324
Ensembl chr17:53,091,933...53,102,342
JBrowse link
G Psmb6 proteasome 20S subunit beta 6 increases expression
multiple interactions
ISO epoxomicin results in increased expression of PSMB6 mRNA
Ascorbic Acid inhibits the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; sulforafan inhibits the reaction [epoxomicin results in increased expression of PSMB6 mRNA]
CTD PMID:27345029 NCBI chr10:57,131,339...57,133,685
Ensembl chr10:57,131,386...57,133,637
JBrowse link
G Psmc4 proteasome 26S subunit, ATPase 4 multiple interactions
increases expression
ISO NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMC4 mRNA] CTD PMID:27345029 NCBI chr 1:84,978,220...84,986,536
Ensembl chr 1:84,978,206...84,986,581
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions
increases ubiquitination
ISO epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of SP1 protein]; epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in increased degradation of SP1 protein]
epoxomicin results in increased ubiquitination of SP1 protein
CTD PMID:17409431 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Taf1 TATA-box binding protein associated factor 1 multiple interactions ISO epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of TAF1 protein] CTD PMID:17409431 NCBI chr  X:71,412,291...71,486,456
Ensembl chr  X:71,412,289...71,485,085
JBrowse link
G Tardbp TAR DNA binding protein multiple interactions ISO epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein] CTD PMID:24477737 NCBI chr 5:165,432,089...165,442,232
Ensembl chr 5:165,432,095...165,442,048
JBrowse link
gefitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO gefitinib results in decreased activity of ABCB11 protein CTD PMID:20829430, PMID:23956101 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; gefitinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Doxorubicin] CTD PMID:17938326 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Adora1 adenosine A1 receptor decreases expression ISO gefitinib results in decreased expression of ADORA1 mRNA CTD PMID:16685379 NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
ISO
EXP
Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein]
Gefitinib results in decreased expression of AKT1 mRNA
Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of AKT1 protein]
CTD PMID:17805209, PMID:19233551, PMID:23255615, PMID:23948867, PMID:24568969, PMID:27087131, PMID:28942004, PMID:30993382, PMID:32370496 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Ar androgen receptor multiple interactions ISO Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] CTD PMID:29383186 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Areg amphiregulin affects response to substance
multiple interactions
decreases response to substance
ISO AREG protein affects the susceptibility to gefitinib
Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA]
AREG protein results in decreased susceptibility to gefitinib
CTD PMID:15496427, PMID:15723263, PMID:16230376, PMID:18980991, PMID:21258428 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
JBrowse link
G Atg5 autophagy related 5 increases expression ISO gefitinib results in increased expression of ATG5 protein CTD PMID:21655094 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Atg7 autophagy related 7 increases expression ISO gefitinib results in increased expression of ATG7 protein CTD PMID:21655094 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Aurka aurora kinase A decreases response to substance
multiple interactions
ISO AURKA results in decreased susceptibility to gefitinib
[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to Gefitinib; [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib
CTD PMID:21216229 NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
JBrowse link
G Aven apoptosis and caspase activation inhibitor affects response to substance ISO AVEN protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 3:103,980,612...104,117,193
Ensembl chr 3:104,042,168...104,117,192
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP Gefitinib results in increased expression of BAX mRNA; Gefitinib results in increased expression of BAX protein CTD PMID:32370496 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2l11 BCL2 like 11 increases response to substance ISO BCL2L11 protein results in increased susceptibility to gefitinib CTD PMID:20237869 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression
decreases expression
multiple interactions
ISO gefitinib results in increased expression of BIRC5 protein
gefitinib results in decreased expression of BIRC5 protein
leptomycin B promotes the reaction [Gefitinib results in decreased expression of BIRC5 protein]; tyrphostin AG 1024 inhibits the reaction [Gefitinib results in increased expression of BIRC5 protein]
CTD PMID:17473213, PMID:28942004 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:25981168 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions
EXP
ISO
gefitinib results in increased expression of CASP3 mRNA; gefitinib results in increased expression of CASP3 protein
EGFR gene mutant form promotes the reaction [gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; gefitinib results in increased cleavage of and results in increased activity of CASP3 protein
CTD PMID:23523951, PMID:27084042, PMID:27639429 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 increases cleavage ISO Gefitinib results in increased cleavage of CASP8 protein CTD PMID:31168030 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Cav1 caveolin 1 increases expression ISO gefitinib results in increased expression of CAV1 mRNA; gefitinib results in increased expression of CAV1 protein CTD PMID:19288272 NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions
ISO gefitinib results in decreased expression of CCND1 protein
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 protein]
CTD PMID:16740687, PMID:17513607, PMID:23948867 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO gefitinib results in decreased expression of CCND3 protein CTD PMID:16740687 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Cd14 CD14 molecule multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; [gefitinib promotes the reaction arsenic trioxide] which results in increased expression of CD14 mRNA; gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]; SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]] CTD PMID:20226526 NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression
ISO betulinic acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein] CTD PMID:30136359 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
decreases expression
ISO gefitinib results in increased expression of CDKN1A protein
leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]
CTD PMID:17513607, PMID:28942004 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression
decreases expression
ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of CDKN1B protein]
gefitinib results in increased expression of CDKN1B protein
gefitinib results in decreased expression of CDKN1B
CTD PMID:14679152, PMID:16322342, PMID:16740687, PMID:17513607 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO gefitinib results in increased expression of CDKN2B mRNA; gefitinib results in increased expression of CDKN2B protein CTD PMID:17513607 NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
JBrowse link
G Cert1 ceramide transporter 1 affects response to substance ISO CERT1 protein affects the susceptibility to Gefitinib CTD PMID:15496427 NCBI chr 2:27,365,145...27,469,797
Ensembl chr 2:27,365,148...27,469,779
JBrowse link
G Cgrrf1 cell growth regulator with ring finger domain 1 increases expression ISO gefitinib results in increased expression of CGRRF1 mRNA CTD PMID:16685379 NCBI chr15:23,619,176...23,639,622
Ensembl chr15:23,619,123...23,639,628
JBrowse link
G Cldn2 claudin 2 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of CLDN2 mRNA CTD PMID:20935109 NCBI chr  X:111,122,552...111,133,188
Ensembl chr  X:111,122,552...111,137,769
JBrowse link
G Coro1c coronin 1C affects response to substance ISO CORO1C protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr12:48,481,741...48,554,054
Ensembl chr12:48,481,750...48,554,052
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO gefitinib affects the localization of CYCS protein CTD PMID:23523951 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases response to substance
increases expression
ISO
EXP
CYP1A1 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of CYP1A1 mRNA
CTD PMID:28652202, PMID:32370496 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of gefitinib CTD PMID:15788367 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 decreases expression ISO gefitinib results in decreased expression of CYP2F1 mRNA CTD PMID:16685379 NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 affects metabolic processing ISO CYP3A5 protein affects the metabolism of gefitinib CTD PMID:15788367 NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
JBrowse link
G Dusp3 dual specificity phosphatase 3 affects response to substance ISO DUSP3 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr10:89,904,578...89,918,296
Ensembl chr10:89,904,560...89,918,427
JBrowse link
G Dusp9 dual specificity phosphatase 9 decreases expression ISO gefitinib results in decreased expression of DUSP9 mRNA CTD PMID:16685379 NCBI chr  X:157,168,143...157,172,068
Ensembl chr  X:157,168,144...157,172,068
JBrowse link
G E2f1 E2F transcription factor 1 decreases expression ISO gefitinib results in decreased expression of E2F1 mRNA; gefitinib results in decreased expression of E2F1 protein CTD PMID:17094457, PMID:18347146 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA] CTD PMID:18424623 NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
JBrowse link
G Egf epidermal growth factor multiple interactions ISO Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]
gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
CTD PMID:15841081, PMID:16243822, PMID:17805209, PMID:17898861, PMID:18927496, PMID:19233551, PMID:19318490, PMID:20088784, PMID:21787763, PMID:23127547, PMID:27087131 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
decreases activity
multiple interactions
decreases phosphorylation
decreases expression
increases response to substance
affects response to substance
ISO
EXP
EGFR gene mutant form results in decreased susceptibility to Gefitinib; EGFR protein mutant form results in decreased susceptibility to Gefitinib
Gefitinib results in decreased activity of EGFR protein
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]
gefitinib results in decreased activity of EGFR protein
Gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased expression of EGFR protein modified form
[Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene; Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of EGFR protein]; Gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein
Gefitinib results in decreased expression of EGFR protein modified form
[[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein; [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein; [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib; betulinic acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form]; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel]; Gefitinib inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]; Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein; KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]
EGFR gene mutant form results in increased susceptibility to gefitinib; EGFR gene polymorphism results in increased susceptibility to gefitinib; EGFR protein mutant form results in increased susceptibility to gefitinib
EGFR gene mutant form affects the susceptibility to Gefitinib; EGFR protein affects the susceptibility to Gefitinib; EGFR protein mutant form affects the susceptibility to Gefitinib
CTD PMID:13680161, PMID:14679152, PMID:15660382, PMID:15723263, PMID:15841081, PMID:15976335, PMID:16115929, PMID:16243822, PMID:16740687, PMID:16824645, PMID:17145836, PMID:17146438, PMID:17236550, PMID:17270025, PMID:17290066, PMID:17473213, PMID:17898861, PMID:17938326, PMID:18271929, PMID:18375820, PMID:18625569, PMID:18771084, PMID:18927496, PMID:19288272, PMID:19318490, PMID:20549698, PMID:20846305, PMID:20935109, PMID:21258428, PMID:21478906, PMID:21544845, PMID:21787763, PMID:23255615, PMID:23948867, PMID:24888374, PMID:27087131, PMID:27447558, PMID:27639429, PMID:28739874, PMID:28942004, PMID:29228391, PMID:29383186, PMID:30136359, PMID:30237564, PMID:30549224, PMID:30993382, PMID:32370496 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Epor erythropoietin receptor increases expression ISO gefitinib results in increased expression of EPOR mRNA CTD PMID:16685379 NCBI chr 8:22,969,737...22,974,468
Ensembl chr 8:22,969,745...22,974,321
JBrowse link
G Eps15 epidermal growth factor receptor pathway substrate 15 increases expression ISO gefitinib results in increased expression of EPS15 mRNA CTD PMID:16685379 NCBI chr 5:128,923,809...129,022,268
Ensembl chr 5:128,923,934...129,022,054
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation
ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]
gefitinib results in decreased phosphorylation of ERBB2 protein
CTD PMID:16243822, PMID:17898861 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
affects response to substance
ISO ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]
ERCC1 gene polymorphism affects the susceptibility to gefitinib
CTD PMID:21264830 NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
JBrowse link
G Esr1 estrogen receptor 1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of ESR1 protein CTD PMID:16261397 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 increases expression
multiple interactions
ISO gefitinib results in increased expression of ESR2 protein
Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]
CTD PMID:20005069, PMID:29383186 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G Faslg Fas ligand multiple interactions
increases response to substance
ISO benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Gefitinib results in increased susceptibility to FASLG protein] CTD PMID:31168030 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fgf6 fibroblast growth factor 6 increases expression ISO gefitinib results in increased expression of FGF6 mRNA CTD PMID:16685379 NCBI chr 4:159,563,798...159,572,333
Ensembl chr 4:159,563,798...159,572,333
JBrowse link
G Foxf1 forkhead box F1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA] CTD PMID:18424623 NCBI chr19:53,012,306...53,016,100
Ensembl chr19:53,012,332...53,016,086
JBrowse link
G Foxo3 forkhead box O3 increases response to substance
increases expression
multiple interactions
ISO
EXP
FOXO3 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of FOXO3 mRNA; Gefitinib results in increased expression of FOXO3 protein; Gefitinib results in increased expression of FOXO3 protein modified form
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of FOXO3 mRNA]
gefitinib results in decreased phosphorylation of and affects the localization of FOXO3 protein
CTD PMID:18089711, PMID:32370496 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO gefitinib results in increased expression of GADD45A mRNA CTD PMID:16685379 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases expression ISO gefitinib results in decreased expression of GADD45G mRNA CTD PMID:16685379 NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
JBrowse link
G Gars glycyl-tRNA synthetase increases expression ISO Gefitinib results in increased expression of GARS1 mRNA CTD PMID:16685379 NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit affects response to substance ISO GCLC protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]] CTD PMID:29228391 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gnb2 G protein subunit beta 2 decreases expression ISO gefitinib results in decreased expression of GNB2 mRNA CTD PMID:16685379 NCBI chr12:22,229,079...22,234,096
Ensembl chr12:22,229,079...22,234,096
JBrowse link
G Gnmt glycine N-methyltransferase multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of GNMT mRNA CTD PMID:20935109 NCBI chr 9:16,565,274...16,568,626
Ensembl chr 9:16,565,225...16,568,627
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Gefitinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression ISO Gefitinib results in decreased expression of GSK3B protein modified form CTD PMID:30136359 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gucy2d guanylate cyclase 2D, retinal decreases expression ISO gefitinib results in decreased expression of GUCY2D mRNA CTD PMID:16685379 NCBI chr10:55,835,695...55,851,235
Ensembl chr10:55,835,695...55,851,235
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of HAVCR1 protein] CTD PMID:23255615 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO
EXP
gefitinib inhibits the reaction [irinotecan metabolite results in increased expression of HBEGF mRNA]; gefitinib inhibits the reaction [irinotecan results in increased expression of HBEGF mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased secretion of HBEGF protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
CTD PMID:15723263, PMID:29228391 NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of HIF1A protein] CTD PMID:21544845 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmox1 heme oxygenase 1 increases expression EXP gefitinib results in increased expression of HMOX1 mRNA; gefitinib results in increased expression of HMOX1 protein CTD PMID:27084042 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions
increases phosphorylation
ISO gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; tyrphostin AG 1024 inhibits the reaction [gefitinib results in increased phosphorylation of IGF1R protein] CTD PMID:17473213 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B protein] CTD PMID:23948867 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM mRNA]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein] CTD PMID:20226526 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
JBrowse link
G Itgav integrin subunit alpha V multiple interactions ISO gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA] CTD PMID:15841081 NCBI chr 3:71,113,269...71,205,958
Ensembl chr 3:71,114,100...71,202,411
JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to gefitinib CTD PMID:21478906 NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA] CTD PMID:18424623 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression ISO gefitinib results in increased expression of KEAP1 mRNA CTD PMID:27639429 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Kras KRAS proto-oncogene, GTPase affects response to substance
decreases response to substance
multiple interactions
ISO KRAS protein mutant form affects the susceptibility to gefitinib
KRAS protein results in decreased susceptibility to gefitinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]
CTD PMID:17270025, PMID:28739874 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Lcn2 lipocalin 2 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of LCN2 protein] CTD PMID:23255615 NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
JBrowse link
G Lepr leptin receptor decreases expression ISO gefitinib results in decreased expression of LEPR mRNA CTD PMID:16685379 NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
JBrowse link
G Lgals9 galectin 9 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of LGALS9 mRNA CTD PMID:20935109 NCBI chr10:64,737,022...64,760,195
Ensembl chr10:64,737,022...64,760,201
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression
ISO
EXP
Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK1 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]
gefitinib results in increased phosphorylation of MAPK1 protein
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]
gefitinib results in decreased expression of MAPK1 protein modified form
CTD PMID:15660382, PMID:16322342, PMID:17145836, PMID:17805209, PMID:17898861, PMID:18927496, PMID:19233551, PMID:19288272, PMID:19318490, PMID:19380191, PMID:20088784, PMID:21258428, PMID:21544845, PMID:21787763, PMID:24568969, PMID:27087131, PMID:28942004, PMID:29383186, PMID:30993382 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation
ISO
EXP
Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK3 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK3 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK3 protein]
gefitinib results in increased phosphorylation of MAPK3 protein
gefitinib results in decreased expression of MAPK3 protein modified form
CTD PMID:15660382, PMID:16322342, PMID:17145836, PMID:17805209, PMID:17898861, PMID:18927496, PMID:19233551, PMID:19288272, PMID:19318490, PMID:19380191, PMID:20088784, PMID:21258428, PMID:21544845, PMID:21787763, PMID:24568969, PMID:27087131, PMID:28942004, PMID:29383186, PMID:30993382 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation ISO gefitinib results in increased phosphorylation of MAPK8 protein CTD PMID:20846305 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Marveld1 MARVEL domain containing 1 decreases response to substance ISO MARVELD1 protein results in decreased susceptibility to Gefitinib CTD PMID:27447558 NCBI chr 1:261,389,804...261,393,736
Ensembl chr 1:261,389,804...261,393,736
JBrowse link
G Mdk midkine multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA] CTD PMID:18424623 NCBI chr 3:80,841,003...80,843,895
Ensembl chr 3:80,841,005...80,842,916
JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression ISO Gefitinib results in increased expression of MICB protein CTD PMID:21951556 NCBI chr 1:79,754,587...79,772,092
Ensembl chr 1:79,754,587...79,772,092
JBrowse link
G Mill1 MHC I like leukocyte 1 increases expression ISO Gefitinib results in increased expression of MICA protein CTD PMID:21951556 NCBI chr 1:79,631,266...79,657,943
Ensembl chr 1:79,631,668...79,657,941
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein CTD PMID:27447558 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Mlh1 mutL homolog 1 decreases expression ISO gefitinib results in decreased expression of MLH1 mRNA CTD PMID:16685379 NCBI chr 8:119,486,655...119,523,716
Ensembl chr 8:119,486,691...119,523,964
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO
EXP
gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]
CTD PMID:15841081, PMID:23127547, PMID:27087131, PMID:29228391 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mr1 major histocompatibility complex, class I-related affects expression ISO gefitinib affects the expression of MR1 mRNA CTD PMID:25811541 NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO gefitinib results in decreased phosphorylation of MTOR protein CTD PMID:21655094 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein] CTD PMID:21544845 NCBI chr 1:214,725,482...214,756,653 JBrowse link
G Mug1 murinoglobulin 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of MUG1 mRNA CTD PMID:20935109 NCBI chr 4:154,676,382...154,729,288
Ensembl chr 4:154,391,647...154,729,310
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO gefitinib results in decreased expression of MYC protein CTD PMID:17513607 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Myh7 myosin heavy chain 7 increases expression EXP gefitinib results in increased expression of MYH7 mRNA; gefitinib results in increased expression of MYH7 protein CTD PMID:27084042 NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
JBrowse link
G Ndufaf4 NADH:ubiquinone oxidoreductase complex assembly factor 4 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of NDUFAF4 mRNA CTD PMID:20935109 NCBI chr 5:39,251,370...39,256,542
Ensembl chr 5:39,251,337...39,257,512
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases expression ISO gefitinib results in decreased expression of NFKB1 mRNA CTD PMID:16685379 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to gefitinib CTD PMID:21216229 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nppa natriuretic peptide A increases expression
multiple interactions
EXP Gefitinib results in increased expression of NPPA mRNA; Gefitinib results in increased expression of NPPA protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of NPPA mRNA]
CTD PMID:32370496 NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
JBrowse link
G Nppb natriuretic peptide B increases expression EXP gefitinib results in increased expression of NPPB mRNA; gefitinib results in increased expression of NPPB protein CTD PMID:27084042 NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
JBrowse link
G Nptx2 neuronal pentraxin 2 decreases expression ISO gefitinib results in decreased expression of NPTX2 mRNA CTD PMID:16685379 NCBI chr12:12,014,638...12,025,547
Ensembl chr12:12,013,911...12,025,549
JBrowse link
G Nrl neural retina leucine zipper decreases expression ISO gefitinib results in decreased expression of NRL mRNA CTD PMID:16685379 NCBI chr15:34,197,115...34,201,408
Ensembl chr15:34,197,193...34,198,921
JBrowse link
G Osmr oncostatin M receptor affects response to substance ISO OSMR protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 2:56,107,491...56,163,522
Ensembl chr 2:56,110,777...56,151,531
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO betulinic acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein]; Gefitinib affects the reaction [Oxaliplatin results in increased cleavage of PARP1 protein]
gefitinib results in increased cleavage of PARP1 protein
CTD PMID:16243822, PMID:23523951, PMID:30136359 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO Gefitinib inhibits the reaction [Folic Acid results in increased expression of PCNA protein] CTD PMID:23255615 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pcnt pericentrin decreases response to substance ISO PCNT protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr20:12,943,523...13,038,615
Ensembl chr20:12,944,786...13,038,431
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA] CTD PMID:18424623 NCBI chr10:94,850,971...94,913,202 JBrowse link
G Pgrmc1 progesterone receptor membrane component 1 decreases response to substance ISO PGRMC1 protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr  X:123,205,869...123,213,880
Ensembl chr  X:123,205,869...123,213,882
JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 affects response to substance ISO PHLDA2 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 1:216,701,345...216,704,479
Ensembl chr 1:216,702,319...216,703,534
JBrowse link
G Plau plasminogen activator, urokinase multiple interactions ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] CTD PMID:23127547 NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
JBrowse link
G Plbd1 phospholipase B domain containing 1 affects response to substance ISO PLBD1 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 4:170,564,387...170,620,681
Ensembl chr 4:170,564,367...170,620,703
JBrowse link
G Pten phosphatase and tensin homolog multiple interactions
increases expression
EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of PTEN mRNA]
Gefitinib results in increased expression of PTEN mRNA; Gefitinib results in increased expression of PTEN protein; Gefitinib results in increased expression of PTEN protein modified form
CTD PMID:32370496 NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of PTGS2 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]
CTD PMID:16322342, PMID:23948867 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin multiple interactions
decreases response to substance
ISO gefitinib results in decreased stability of and results in decreased expression of PTTG1 protein
PTTG1 protein results in decreased susceptibility to gefitinib
CTD PMID:23523951 NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
JBrowse link
G Qsox1 quiescin sulfhydryl oxidase 1 increases expression ISO gefitinib results in increased expression of QSOX1 mRNA CTD PMID:16685379 NCBI chr13:73,423,396...73,460,890
Ensembl chr13:73,423,397...73,460,935
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases expression
ISO betulinic acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [betulinic acid results in decreased expression of RB1 protein modified form] CTD PMID:30136359 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rbm7 RNA binding motif protein 7 affects response to substance ISO RBM7 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:52,823,094...52,828,134
Ensembl chr 8:52,823,096...52,828,134
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases response to substance
ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]
RELA protein results in decreased susceptibility to gefitinib
CTD PMID:19318490, PMID:21216229 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rpa1 replication protein A1 increases expression ISO gefitinib results in increased expression of RPA1 mRNA CTD PMID:16685379 NCBI chr10:62,140,419...62,191,518
Ensembl chr10:62,140,419...62,191,512
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of RPS6KB1 protein CTD PMID:21655094 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Rrm1 ribonucleotide reductase catalytic subunit M1 affects response to substance ISO RRM1 gene polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:167,538,387...167,562,688
Ensembl chr 1:167,538,263...167,562,688
JBrowse link
G RT1-CE5 RT1 class I, locus CE5 affects expression ISO gefitinib affects the expression of HLA-F mRNA CTD PMID:25811541 NCBI chr20:4,892,702...4,896,993
Ensembl chr20:4,892,702...4,896,991
JBrowse link
G RT1-Db1 RT1 class II, locus Db1 affects expression ISO gefitinib affects the expression of HLA-DRB1 mRNA CTD PMID:25811541 NCBI chr20:4,087,621...4,097,190
Ensembl chr20:4,087,618...4,097,190
JBrowse link
G RT1-DOa RT1 class II, locus DOa affects expression ISO gefitinib affects the expression of HLA-DOA mRNA CTD PMID:25811541 NCBI chr20:3,889,106...3,892,360
Ensembl chr20:3,889,370...3,892,449
JBrowse link
G S100a6 S100 calcium binding protein A6 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A6 mRNA CTD PMID:20935109 NCBI chr 2:190,007,013...190,008,512
Ensembl chr 2:190,007,216...190,008,511
JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A8 mRNA; [gefitinib co-treated with naphthalene] affects the expression of S100A8 protein CTD PMID:20935109 NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
JBrowse link
G Serpinf1 serpin family F member 1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA] CTD PMID:18424623 NCBI chr10:62,241,750...62,254,145
Ensembl chr10:62,241,756...62,254,287
JBrowse link
G Sfn stratifin decreases expression ISO gefitinib results in decreased expression of SFN mRNA CTD PMID:16685379 NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
JBrowse link
G Ski SKI proto-oncogene increases expression ISO gefitinib results in increased expression of SKI mRNA CTD PMID:16685379 NCBI chr 5:172,556,196...172,623,878
Ensembl chr 5:172,559,135...172,623,899
JBrowse link
G Slc10a3 solute carrier family 10, member 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SLC10A3 mRNA CTD PMID:20935109 NCBI chr  X:156,335,385...156,340,256
Ensembl chr  X:156,336,450...156,340,234
JBrowse link
G Snai2 snail family transcriptional repressor 2 affects response to substance ISO SNAI2 protein affects the susceptibility to gefitinib CTD PMID:21037017 NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO gefitinib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:14,890,318...14,895,907
Ensembl chr 5:14,890,408...14,895,907
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression
ISO [Gefitinib co-treated with Cisplatin] results in decreased expression of SQSTM1 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein] CTD PMID:25979647, PMID:27639429 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein CTD PMID:27447558 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of STAT3 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of STAT3 protein]
CTD PMID:19318490, PMID:21787763, PMID:23948867 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Synpo synaptopodin multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SYNPO mRNA CTD PMID:20935109 NCBI chr18:55,863,081...55,921,412
Ensembl chr18:55,865,467...55,916,220
JBrowse link
G Tek TEK receptor tyrosine kinase multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA] CTD PMID:18424623 NCBI chr 5:113,725,717...113,852,799
Ensembl chr 5:113,725,717...113,852,799
JBrowse link
G Tert telomerase reverse transcriptase decreases expression ISO gefitinib results in decreased expression of TERT mRNA CTD PMID:17094457 NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124, PMID:21951556 NCBI chr17:24,653,342...24,670,457
Ensembl chr17:24,654,902...24,670,457
JBrowse link
G Tgfa transforming growth factor alpha decreases response to substance
multiple interactions
ISO TGFA protein results in decreased susceptibility to gefitinib
gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; gefitinib inhibits the reaction [irinotecan metabolite results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [irinotecan results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]
CTD PMID:15723263, PMID:16230376, PMID:18424623, PMID:21266357 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF mRNA]; Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; Gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]; Gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA] CTD PMID:15841081, PMID:23948867 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B decreases expression ISO gefitinib results in decreased expression of TNFRSF1B mRNA CTD PMID:16685379 NCBI chr 5:163,136,390...163,167,299
Ensembl chr 5:163,136,390...163,167,299
JBrowse link
G Tnni3 troponin I3, cardiac type increases secretion EXP Gefitinib results in increased secretion of TNNI3 protein CTD PMID:32370496 NCBI chr 1:72,882,806...72,886,490
Ensembl chr 1:72,882,806...72,886,488
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
affects response to substance
ISO
EXP
[TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein]
gefitinib results in increased expression of TP53 mRNA; gefitinib results in increased expression of TP53 protein
TP53 protein affects the susceptibility to gefitinib
CTD PMID:21216229, PMID:27084042, PMID:29383186 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Trim23 tripartite motif-containing 23 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TRIM23 mRNA CTD PMID:20935109 NCBI chr 2:34,255,300...34,288,140
Ensembl chr 2:34,255,305...34,288,139
JBrowse link
G Tsc22d1 TSC22 domain family, member 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TSC22D1 mRNA CTD PMID:20935109 NCBI chr15:58,554,358...58,658,156
Ensembl chr15:58,554,374...58,658,153
JBrowse link
G Twist1 twist family bHLH transcription factor 1 affects response to substance ISO TWIST1 protein affects the susceptibility to Gefitinib CTD PMID:30993382 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
G Tyms thymidylate synthetase decreases expression
multiple interactions
ISO Gefitinib results in decreased expression of TYMS mRNA; Gefitinib results in decreased expression of TYMS protein
betulinic acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [betulinic acid results in decreased expression of TYMS protein]; TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]
CTD PMID:18347146, PMID:30136359 NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
JBrowse link
G Ulbp1 UL16 binding protein 1 multiple interactions
increases expression
ISO Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib results in increased expression of ULBP1 mRNA]
Gefitinib results in increased expression of ULBP1 mRNA; Gefitinib results in increased expression of ULBP1 protein
CTD PMID:21499124, PMID:21951556 NCBI chr 1:1,181,301...1,200,526
Ensembl chr 1:1,180,932...1,220,916
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression
ISO
EXP
gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]
gefitinib results in decreased expression of VEGFA protein
CTD PMID:15660382, PMID:18424623 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions ISO Gefitinib inhibits the reaction [Folic Acid results in increased expression of VIM protein] CTD PMID:23255615 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xrcc1 X-ray repair cross complementing 1 affects response to substance ISO XRCC1 protein polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678
JBrowse link
G Zc3h3 zinc finger CCCH type containing 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of ZC3H3 mRNA CTD PMID:20935109 NCBI chr 7:116,787,762...116,872,536
Ensembl chr 7:116,787,766...116,872,511
JBrowse link
G Zfp35 zinc finger protein 35 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of ZFP35 mRNA CTD PMID:20935109 NCBI chr18:15,883,182...15,898,803
Ensembl chr18:15,883,182...15,898,821
JBrowse link
Ku-0063794 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO Ku 0063794 results in decreased phosphorylation of AKT1 protein CTD PMID:22885370 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with PD 0325901] results in decreased phosphorylation of EIF4EBP1 protein; Ku 0063794 inhibits the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:22415236 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation
ISO [Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of RPS6 protein
Ku 0063794 results in decreased phosphorylation of RPS6 protein
CTD PMID:22415236, PMID:22885370 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
linezolid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alas2 5'-aminolevulinate synthase 2 decreases expression EXP Linezolid results in decreased expression of ALAS2 mRNA CTD PMID:21296123 NCBI chr  X:23,167,576...23,187,356
Ensembl chr  X:23,167,696...23,187,341
JBrowse link
G Camkv CaM kinase-like vesicle-associated decreases expression EXP Linezolid results in decreased expression of CAMKV mRNA CTD PMID:21296123 NCBI chr 8:116,715,755...116,730,061
Ensembl chr 8:116,715,755...116,730,061
JBrowse link
G Cdc25b cell division cycle 25B decreases expression EXP Linezolid results in decreased expression of CDC25B mRNA CTD PMID:21296123 NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339
JBrowse link
G Cfap77 cilia and flagella associated protein 77 decreases expression EXP Linezolid results in decreased expression of CFAP77 mRNA CTD PMID:21296123 NCBI chr 3:7,508,500...7,632,311
Ensembl chr 3:7,508,496...7,632,345
JBrowse link
G Cib2 calcium and integrin binding family member 2 decreases expression EXP Linezolid results in decreased expression of CIB2 mRNA CTD PMID:21296123 NCBI chr 8:59,123,078...59,139,946
Ensembl chr 8:59,123,079...59,139,946
JBrowse link
G Crym crystallin, mu decreases expression EXP Linezolid results in decreased expression of CRYM mRNA CTD PMID:21296123 NCBI chr 1:189,944,895...189,960,069
Ensembl chr 1:189,944,895...189,960,073
JBrowse link
G Csad cysteine sulfinic acid decarboxylase decreases expression EXP Linezolid results in decreased expression of CSAD mRNA CTD PMID:21296123 NCBI chr 7:143,781,520...143,810,880
Ensembl chr 7:143,781,702...143,793,970
JBrowse link
G Dars2 aspartyl-tRNA synthetase 2 (mitochondrial) decreases expression EXP Linezolid results in decreased expression of DARS2 mRNA CTD PMID:21296123 NCBI chr13:78,857,638...78,885,464
Ensembl chr13:78,857,638...78,885,464
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 decreases expression EXP Linezolid results in decreased expression of HBA-A2 mRNA CTD PMID:21296123 NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
JBrowse link
G Hbb hemoglobin subunit beta decreases expression EXP Linezolid results in decreased expression of HBB mRNA CTD PMID:21296123 NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
JBrowse link
G IgG-2a gamma-2a immunoglobulin heavy chain decreases expression EXP Linezolid results in decreased expression of IGG-2A mRNA CTD PMID:21296123
G Kifc1 kinesin family member C1 decreases expression EXP Linezolid results in decreased expression of KIFC1 mRNA CTD PMID:21296123 NCBI chr20:5,509,059...5,526,175
Ensembl chr20:5,509,059...5,526,175
JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression EXP Linezolid results in decreased expression of MKI67 mRNA CTD PMID:21296123 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Mlc1 modulator of VRAC current 1 decreases expression EXP Linezolid results in decreased expression of MLC1 mRNA CTD PMID:21296123 NCBI chr 7:129,949,984...129,970,314
Ensembl chr 7:129,949,967...129,970,550
JBrowse link
G Phlda3 pleckstrin homology-like domain, family A, member 3 decreases expression EXP Linezolid results in decreased expression of PHLDA3 mRNA CTD PMID:21296123 NCBI chr13:52,588,917...52,592,002
Ensembl chr13:52,588,917...52,592,001
JBrowse link
G Prcp prolylcarboxypeptidase decreases expression EXP Linezolid results in decreased expression of PRCP mRNA CTD PMID:21296123 NCBI chr 1:157,701,089...157,750,177
Ensembl chr 1:157,701,089...157,750,169
JBrowse link
G Prtg protogenin decreases expression EXP Linezolid results in decreased expression of PRTG mRNA CTD PMID:21296123 NCBI chr 8:79,489,790...79,593,806
Ensembl chr 8:79,489,790...79,593,806
JBrowse link
G Slc22a8 solute carrier family 22 member 8 decreases expression EXP Linezolid results in decreased expression of SLC22A8 mRNA CTD PMID:21296123 NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
JBrowse link
G Stac3 SH3 and cysteine rich domain 3 decreases expression EXP Linezolid results in decreased expression of STAC3 mRNA CTD PMID:21296123 NCBI chr 7:70,807,427...70,815,271
Ensembl chr 7:70,807,867...70,815,270
JBrowse link
G Trip13 thyroid hormone receptor interactor 13 decreases expression EXP Linezolid results in decreased expression of TRIP13 mRNA CTD PMID:21296123 NCBI chr 1:31,967,980...32,012,923
Ensembl chr 1:31,967,978...32,012,919
JBrowse link
G Zfyve19 zinc finger FYVE-type containing 19 decreases expression EXP Linezolid results in decreased expression of ZFYVE19 mRNA CTD PMID:21296123 NCBI chr 3:111,013,856...111,021,841
Ensembl chr 3:111,013,856...111,021,841
JBrowse link
linsidomine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca5 ATP binding cassette subfamily A member 5 increases oxidation EXP linsidomine results in increased oxidation of ABCA5 protein CTD PMID:28086193 NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant increases oxidation EXP linsidomine results in increased oxidation of ACP5 protein CTD PMID:28086193 NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396
JBrowse link
G Agrn agrin increases oxidation EXP linsidomine results in increased oxidation of AGRN protein CTD PMID:28086193 NCBI chr 5:173,589,910...173,622,813
Ensembl chr 5:173,589,819...173,622,645
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases metabolic processing
increases phosphorylation
multiple interactions
ISO
EXP
linsidomine results in increased metabolism of AKT1 protein
linsidomine results in increased phosphorylation of AKT1 protein
wortmannin inhibits the reaction [linsidomine results in increased phosphorylation of AKT1 protein]
linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]
CTD PMID:17302912, PMID:19682478 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Ap2a2 adaptor related protein complex 2 subunit alpha 2 increases oxidation EXP linsidomine results in increased oxidation of AP2A2 protein CTD PMID:28086193 NCBI chr 1:214,534,217...214,607,497
Ensembl chr 1:214,534,284...214,606,169
JBrowse link
G Apba1 amyloid beta precursor protein binding family A member 1 increases oxidation EXP linsidomine results in increased oxidation of APBA1 protein CTD PMID:28086193 NCBI chr 1:241,594,565...241,796,512
Ensembl chr 1:241,594,565...241,796,513
JBrowse link
G Apob apolipoprotein B increases oxidation EXP linsidomine results in increased oxidation of APOB protein CTD PMID:28086193 NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 increases oxidation EXP linsidomine results in increased oxidation of ARNT2 protein CTD PMID:28086193 NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
JBrowse link
G Atf4 activating transcription factor 4 increases expression ISO linsidomine results in increased expression of ATF4 mRNA CTD PMID:21703327 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Avp arginine vasopressin increases expression EXP linsidomine results in increased expression of AVP mRNA CTD PMID:10460269 NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
JBrowse link
G Avpr1b arginine vasopressin receptor 1B increases oxidation EXP linsidomine results in increased oxidation of AVPR1B protein CTD PMID:28086193 NCBI chr13:48,367,307...48,378,831
Ensembl chr13:48,367,307...48,378,831
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions
ISO linsidomine results in increased expression of BAX
Selegiline inhibits the reaction [linsidomine results in increased expression of BAX protein]
MT1A inhibits the reaction [linsidomine results in increased expression of BAX]
CTD PMID:12880480, PMID:16291239 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions
ISO linsidomine results in decreased expression of BCL2; linsidomine results in decreased expression of BCL2 protein
[linsidomine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 mRNA; [linsidomine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 protein; Selegiline inhibits the reaction [linsidomine results in decreased expression of BCL2 protein]
MT1A inhibits the reaction [linsidomine results in decreased expression of BCL2]; Plant Extracts inhibits the reaction [linsidomine results in decreased expression of BCL2 protein]
CTD PMID:7706495, PMID:12880480, PMID:16291239, PMID:23174672 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Brca2 BRCA2, DNA repair associated increases oxidation EXP linsidomine results in increased oxidation of BRCA2 protein CTD PMID:28086193 NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
JBrowse link
G Cacna1c calcium voltage-gated channel subunit alpha1 C multiple interactions ISO [linsidomine co-treated with Peroxynitrous Acid] results in increased nitrosation of CACNA1C protein CTD PMID:17551092 NCBI chr 4:150,635,808...151,270,790
Ensembl chr 4:150,641,066...150,829,913
JBrowse link
G Cacna1e calcium voltage-gated channel subunit alpha1 E increases oxidation EXP linsidomine results in increased oxidation of CACNA1E protein CTD PMID:28086193 NCBI chr13:71,899,445...72,534,992
Ensembl chr13:71,906,702...72,367,980
JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H increases oxidation EXP linsidomine results in increased oxidation of CACNA1H protein CTD PMID:28086193 NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 increases oxidation EXP linsidomine results in increased oxidation of CACNB2 protein CTD PMID:28086193 NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682
JBrowse link
G Calca calcitonin-related polypeptide alpha increases response to substance EXP CALCA protein results in increased susceptibility to linsidomine CTD PMID:8581270 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
JBrowse link
G Carm1 coactivator-associated arginine methyltransferase 1 increases oxidation EXP linsidomine results in increased oxidation of CARM1 protein CTD PMID:28086193 NCBI chr 8:22,577,723...22,622,555
Ensembl chr 8:22,577,715...22,622,560
JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions
increases expression
increases cleavage
ISO
EXP
linsidomine results in increased activity of CASP3 protein
Melatonin inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]; MT1A inhibits the reaction [linsidomine results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [linsidomine results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [linsidomine results in increased expression of CASP3 protein modified form]; Selegiline inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]; Selegiline inhibits the reaction [linsidomine results in increased expression of CASP3 protein]; Ubiquinone inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]
linsidomine results in increased expression of CASP3 mRNA; linsidomine results in increased expression of CASP3 protein; linsidomine results in increased expression of CASP3 protein modified form
CTD PMID:12880480, PMID:15686499, PMID:16291239, PMID:19038279, PMID:23174672 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions ISO linsidomine results in decreased activity of and results in decreased expression of CAT protein; Plant Extracts inhibits the reaction [linsidomine results in decreased activity of and results in decreased expression of CAT protein]
CAT protein inhibits the reaction [linsidomine results in decreased expression of CCND1 mRNA]; CAT protein inhibits the reaction [linsidomine results in decreased expression of CCND1 protein]
CTD PMID:12600834, PMID:23174672 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
ISO CAT protein inhibits the reaction [linsidomine results in decreased expression of CCND1 mRNA]; CAT protein inhibits the reaction [linsidomine results in decreased expression of CCND1 protein]
linsidomine results in decreased expression of CCND1 mRNA; linsidomine results in decreased expression of CCND1 protein
CTD PMID:12600834 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cep83 centrosomal protein 83 increases oxidation EXP linsidomine results in increased oxidation of CEP83 protein CTD PMID:28086193 NCBI chr 7:35,739,553...35,847,618
Ensembl chr 7:35,773,928...35,847,617
JBrowse link
G Cep95 centrosomal protein 95 increases oxidation EXP linsidomine results in increased oxidation of CEP95 protein CTD PMID:28086193 NCBI chr10:94,988,362...95,017,774
Ensembl chr10:94,988,362...95,016,344
JBrowse link
G Clrn1 clarin 1 increases oxidation EXP linsidomine results in increased oxidation of CLRN1 protein CTD PMID:28086193 NCBI chr 2:149,049,925...149,088,787
Ensembl chr 2:149,049,925...149,088,787
JBrowse link
G Clu clusterin increases oxidation EXP linsidomine results in increased oxidation of CLU protein CTD PMID:28086193 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
JBrowse link
G Crh corticotropin releasing hormone multiple interactions
increases expression
EXP CRH protein affects the reaction [linsidomine results in increased secretion of POMC protein alternative form]
linsidomine results in increased expression of CRH mRNA
CTD PMID:10460269 NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
JBrowse link
G Crhr1 corticotropin releasing hormone receptor 1 increases expression EXP linsidomine results in increased expression of CRHR1 mRNA CTD PMID:10460269 NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645
JBrowse link
G Cttnbp2 cortactin binding protein 2 increases oxidation EXP linsidomine results in increased oxidation of CTTNBP2 protein CTD PMID:28086193 NCBI chr 4:42,932,897...43,096,454
Ensembl chr 4:42,932,903...43,096,399
JBrowse link
G Cycs cytochrome c, somatic affects localization
multiple interactions
ISO linsidomine affects the localization of CYCS protein
Selegiline inhibits the reaction [linsidomine affects the localization of CYCS protein]
CTD PMID:12880480 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO linsidomine results in increased expression of DDIT3 mRNA CTD PMID:21703327 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Ddx52 DExD-box helicase 52 increases oxidation EXP linsidomine results in increased oxidation of DDX52 protein CTD PMID:28086193 NCBI chr10:71,253,667...71,276,397
Ensembl chr10:71,253,598...71,277,277
JBrowse link
G Dlgap4 DLG associated protein 4 increases oxidation EXP linsidomine results in increased oxidation of DLGAP4 protein CTD PMID:28086193 NCBI chr 3:152,752,091...152,846,118
Ensembl chr 3:152,752,091...152,846,118
JBrowse link
G Dnah7 dynein, axonemal, heavy chain 7 increases oxidation EXP linsidomine results in increased oxidation of DNAH7 protein CTD PMID:28086193 NCBI chr 9:60,070,087...60,330,121
NCBI chr 9:59,564,253...59,595,347
Ensembl chr 9:60,070,739...60,330,125
Ensembl chr 9:60,070,739...60,330,125
JBrowse link
G Dnmt1 DNA methyltransferase 1 increases oxidation EXP linsidomine results in increased oxidation of DNMT1 protein CTD PMID:28086193 NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
JBrowse link
G Dscam DS cell adhesion molecule increases oxidation EXP linsidomine results in increased oxidation of DSCAM protein CTD PMID:28086193 NCBI chr11:37,004,776...37,599,866
Ensembl chr11:37,004,902...37,253,776
JBrowse link
G E2f2 E2F transcription factor 2 decreases activity ISO linsidomine results in decreased activity of E2F2 protein CTD PMID:12600834 NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265
JBrowse link
G Eaf2 ELL associated factor 2 increases oxidation EXP linsidomine results in increased oxidation of EAF2 protein CTD PMID:28086193 NCBI chr11:66,878,658...66,923,092
Ensembl chr11:66,878,658...66,923,092
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases phosphorylation ISO linsidomine results in increased phosphorylation of EIF2AK3 protein CTD PMID:21703327 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation ISO linsidomine results in increased phosphorylation of EIF2S1 protein CTD PMID:21703327 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Ephx2 epoxide hydrolase 2 increases oxidation EXP linsidomine results in increased oxidation of EPHX2 protein CTD PMID:28086193 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
JBrowse link
G Evl Enah/Vasp-like increases oxidation EXP linsidomine results in increased oxidation of EVL protein CTD PMID:28086193 NCBI chr 6:132,470,283...132,590,242
Ensembl chr 6:132,510,757...132,590,241
JBrowse link
G Fam221b family with sequence similarity 221, member B increases oxidation EXP linsidomine results in increased oxidation of FAM221B protein CTD PMID:28086193 NCBI chr 5:59,156,079...59,165,440
Ensembl chr 5:59,156,071...59,165,160
JBrowse link
G Faslg Fas ligand multiple interactions ISO [linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter] CTD PMID:10811113 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fasn fatty acid synthase increases oxidation EXP linsidomine results in increased oxidation of FASN protein CTD PMID:28086193 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fra10ac1 FRA10A associated CGG repeat 1 increases oxidation EXP linsidomine results in increased oxidation of FRA10AC1 protein CTD PMID:28086193 NCBI chr 1:256,881,688...256,913,617
Ensembl chr 1:256,881,771...256,914,260
JBrowse link
G Gabra5 gamma-aminobutyric acid type A receptor subunit alpha 5 increases oxidation EXP linsidomine results in increased oxidation of GABRA5 protein CTD PMID:28086193 NCBI chr 1:112,833,941...112,947,482
Ensembl chr 1:112,833,944...112,947,451
JBrowse link
G Glg1 golgi glycoprotein 1 increases oxidation EXP linsidomine results in increased oxidation of GLG1 protein CTD PMID:28086193 NCBI chr19:42,983,879...43,088,074
Ensembl chr19:42,983,869...43,090,841
JBrowse link
G Golga4 golgin A4 increases oxidation EXP linsidomine results in increased oxidation of GOLGA4 protein CTD PMID:28086193 NCBI chr 8:127,171,221...127,248,938
Ensembl chr 8:127,171,537...127,248,538
JBrowse link
G Grm7 glutamate metabotropic receptor 7 increases oxidation EXP linsidomine results in increased oxidation of GRM7 protein CTD PMID:28086193 NCBI chr 4:142,452,616...143,368,460
Ensembl chr 4:142,780,987...143,367,578
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression EXP linsidomine results in increased expression of GSTA2; linsidomine results in increased expression of GSTA2 protein CTD PMID:12446173, PMID:15357004 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gucy2d guanylate cyclase 2D, retinal increases oxidation EXP linsidomine results in increased oxidation of GUCY2E protein CTD PMID:28086193 NCBI chr10:55,835,695...55,851,235
Ensembl chr10:55,835,695...55,851,235
JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha increases oxidation EXP linsidomine results in increased oxidation of HADHA protein CTD PMID:28086193 NCBI chr 6:27,589,840...27,628,921
Ensembl chr 6:27,589,657...27,629,175
JBrowse link
G Hgs hepatocyte growth factor-regulated tyrosine kinase substrate increases oxidation EXP linsidomine results in increased oxidation of HGS protein CTD PMID:28086193 NCBI chr10:109,638,944...109,657,460
Ensembl chr10:109,638,767...109,657,456
JBrowse link
G Hist1h2bg histone cluster 1, H2bg increases oxidation EXP linsidomine results in increased oxidation of HIST1H2BG protein CTD PMID:28086193 NCBI chr17:43,817,316...43,817,717
Ensembl chr17:43,817,378...43,817,720
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
ISO [linsidomine co-treated with Nitroprusside] results in increased expression of HMOX1 mRNA; [linsidomine co-treated with S-Nitrosoglutathione] results in increased expression of HMOX1 mRNA
linsidomine results in increased expression of HMOX1 mRNA
CTD PMID:8764571, PMID:10423162 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hnrnpm heterogeneous nuclear ribonucleoprotein M increases oxidation EXP linsidomine results in increased oxidation of HNRNPM protein CTD PMID:28086193 NCBI chr 7:18,516,253...18,554,536
Ensembl chr 7:18,516,512...18,554,227
JBrowse link
G Hormad1 HORMA domain containing 1 increases oxidation EXP linsidomine results in increased oxidation of HORMAD1 protein CTD PMID:28086193 NCBI chr 2:197,681,820...197,720,197
Ensembl chr 2:197,682,000...197,719,254
JBrowse link
G Il6 interleukin 6 multiple interactions
increases secretion
ISO TLR4 gene mutant form inhibits the reaction [linsidomine results in increased secretion of IL6 protein] CTD PMID:29175419 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ilk integrin-linked kinase increases oxidation EXP linsidomine results in increased oxidation of ILK protein CTD PMID:28086193 NCBI chr 1:170,578,941...170,585,192
Ensembl chr 1:170,578,889...170,585,189
JBrowse link
G Insr insulin receptor multiple interactions
increases metabolic processing
ISO linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]
linsidomine results in increased metabolism of INSR protein
CTD PMID:19682478 NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
JBrowse link
G Iqsec3 IQ motif and Sec7 domain ArfGEF 3 increases oxidation EXP linsidomine results in increased oxidation of IQSEC3 protein CTD PMID:28086193 NCBI chr 4:153,948,052...154,044,493
Ensembl chr 4:153,948,055...154,044,493
JBrowse link
G Irs1 insulin receptor substrate 1 multiple interactions ISO linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of IRS1 protein]; linsidomine results in increased metabolism of and results in decreased expression of IRS1 protein CTD PMID:19682478 NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
JBrowse link
G Itpr1 inositol 1,4,5-trisphosphate receptor, type 1 multiple interactions
increases expression
ISO Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA]; Dactinomycin inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA] CTD PMID:17241155 NCBI chr 4:140,247,297...140,580,749
Ensembl chr 4:140,247,313...140,580,748
JBrowse link
G Itpr3 inositol 1,4,5-trisphosphate receptor, type 3 increases oxidation EXP linsidomine results in increased oxidation of ITPR3 protein CTD PMID:28086193 NCBI chr20:5,645,894...5,711,702
Ensembl chr20:5,646,097...5,711,702
JBrowse link
G Kat6a lysine acetyltransferase 6A increases oxidation EXP linsidomine results in increased oxidation of KAT6A protein CTD PMID:28086193 NCBI chr16:73,942,669...74,020,750
Ensembl chr16:73,943,455...74,023,005
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects response to substance ISO KEAP1 mRNA affects the susceptibility to linsidomine CTD PMID:16092930 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Khdrbs2 KH RNA binding domain containing, signal transduction associated 2 increases oxidation EXP linsidomine results in increased oxidation of KHDRBS2 protein CTD PMID:28086193 NCBI chr 9:39,501,431...40,008,707
Ensembl chr 9:39,539,530...40,008,680
JBrowse link
G Klk8 kallikrein related-peptidase 8 increases oxidation EXP linsidomine results in increased oxidation of KLK8 protein CTD PMID:28086193 NCBI chr 1:99,735,168...99,742,011
Ensembl chr 1:99,734,993...99,742,009
JBrowse link
G Mprip myosin phosphatase Rho interacting protein increases oxidation EXP linsidomine results in increased oxidation of MPRIP protein CTD PMID:28086193 NCBI chr10:46,018,397...46,133,580
Ensembl chr10:46,018,659...46,133,571
JBrowse link
G Mt1 metallothionein 1 multiple interactions
decreases response to substance
increases expression
ISO MT1A inhibits the reaction [linsidomine results in decreased expression of BCL2]; MT1A inhibits the reaction [linsidomine results in increased activity of CASP3 protein]; MT1A inhibits the reaction [linsidomine results in increased expression of BAX]
Selegiline inhibits the reaction [linsidomine results in increased expression of MT1 protein]
MT1 protein results in decreased susceptibility to linsidomine
CTD PMID:12880480, PMID:16291239 NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
JBrowse link
G Mtfr1 mitochondrial fission regulator 1 increases oxidation EXP linsidomine results in increased oxidation of MTFR1 protein CTD PMID:28086193 NCBI chr 2:104,005,696...104,040,914
Ensembl chr 2:104,020,955...104,039,198
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases oxidation EXP linsidomine results in increased oxidation of MTOR protein CTD PMID:28086193 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Mybpc3 myosin binding protein C3 increases oxidation EXP linsidomine results in increased oxidation of MYBPC3 protein CTD PMID:28086193 NCBI chr 3:79,940,509...79,958,731
Ensembl chr 3:79,940,561...79,958,730
JBrowse link
G Nat1 N-acetyltransferase 1 decreases activity ISO linsidomine results in decreased activity of NAT1 protein CTD PMID:14672957 NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
JBrowse link
G Nbr1 NBR1, autophagy cargo receptor increases oxidation EXP linsidomine results in increased oxidation of NBR1 protein CTD PMID:28086193 NCBI chr10:89,455,202...89,483,791
Ensembl chr10:89,459,650...89,484,080
JBrowse link
G Nf1 neurofibromin 1 increases oxidation EXP linsidomine results in increased oxidation of NF1 protein CTD PMID:28086193 NCBI chr10:66,732,460...66,928,706
Ensembl chr10:66,690,133...66,928,903
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
decreases response to substance
ISO
EXP
[linsidomine results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine
linsidomine results in increased localization of and results in increased activity of NFE2L2 protein
NFE2L2 results in decreased susceptibility to linsidomine
1,2-dithiol-3-thione promotes the reaction [NFE2L2 results in decreased susceptibility to linsidomine]
NFE2L2 protein results in decreased susceptibility to linsidomine
CTD PMID:12446173, PMID:16092930, PMID:18367636 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nos1 nitric oxide synthase 1 increases expression
increases oxidation
EXP linsidomine results in increased expression of NOS1 mRNA
linsidomine results in increased oxidation of NOS1 protein
CTD PMID:19038279, PMID:28086193 NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
JBrowse link
G Nos2 nitric oxide synthase 2 increases expression
multiple interactions
ISO linsidomine results in increased expression of NOS2 protein
[linsidomine results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites; [Plant Extracts inhibits the reaction [linsidomine results in increased expression of NOS2 protein]] which results in decreased chemical synthesis of Nitrites; Plant Extracts inhibits the reaction [linsidomine results in increased expression of NOS2 protein]
CTD PMID:23174672 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 increases expression EXP linsidomine results in increased expression of NR4A1 mRNA CTD PMID:10460269 NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
JBrowse link
G Oma1 OMA1 zinc metallopeptidase increases oxidation EXP linsidomine results in increased oxidation of OMA1 protein CTD PMID:28086193 NCBI chr 5:122,847,624...122,900,475
Ensembl chr 5:122,847,645...122,900,475
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases expression
ISO Selegiline inhibits the reaction [linsidomine results in decreased expression of PARP1 protein] CTD PMID:12880480 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pcna proliferating cell nuclear antigen decreases expression ISO linsidomine results in decreased expression of PCNA protein CTD PMID:12600834 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pds5a PDS5 cohesin associated factor A increases oxidation EXP linsidomine results in increased oxidation of PDS5A protein CTD PMID:28086193 NCBI chr14:44,185,445...44,282,308
Ensembl chr14:44,185,446...44,280,079
JBrowse link
G Pepd peptidase D multiple interactions ISO linsidomine results in increased phosphorylation of and results in increased activity of PEPD protein CTD PMID:16167338 NCBI chr 1:90,820,670...91,285,128 JBrowse link
G Pi4ka phosphatidylinositol 4-kinase alpha increases oxidation EXP linsidomine results in increased oxidation of PI4KA protein CTD PMID:28086193 NCBI chr11:87,858,323...87,975,549
Ensembl chr11:87,858,453...87,973,422
JBrowse link
G Pif1 PIF1 5'-to-3' DNA helicase increases oxidation EXP linsidomine results in increased oxidation of PIF1 protein CTD PMID:28086193 NCBI chr 8:71,124,477...71,133,460
Ensembl chr 8:71,125,414...71,132,629
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO linsidomine inhibits the reaction [INS1 protein binds to PIK3R1 protein]; linsidomine inhibits the reaction [INS1 protein results in increased activity of PIK3R1 protein] CTD PMID:19682478 NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
JBrowse link
G Plb1 phospholipase B1 increases oxidation EXP linsidomine results in increased oxidation of PLB1 protein CTD PMID:28086193 NCBI chr 6:25,375,699...25,507,108
Ensembl chr 6:25,397,537...25,507,073
JBrowse link
G Plekhg5 pleckstrin homology and RhoGEF domain containing G5 increases oxidation EXP linsidomine results in increased oxidation of PLEKHG5 protein CTD PMID:28086193 NCBI chr 5:169,244,778...169,288,310
Ensembl chr 5:169,244,778...169,288,309
JBrowse link
G Pomc proopiomelanocortin multiple interactions
increases secretion
EXP CRH protein affects the reaction [linsidomine results in increased secretion of POMC protein alternative form] CTD PMID:10460269 NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
JBrowse link
G Ppp1r37 protein phosphatase 1, regulatory subunit 37 increases oxidation EXP linsidomine results in increased oxidation of PPP1R37 protein CTD PMID:28086193 NCBI chr 1:80,439,718...80,471,527
Ensembl chr 1:80,439,718...80,471,527
JBrowse link
G Prkca protein kinase C, alpha multiple interactions EXP [linsidomine co-treated with Staurosporine] results in decreased expression of PRKCA protein; Staurosporine inhibits the reaction [linsidomine results in increased phosphorylation of PRKCA protein] CTD PMID:11994256 NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase increases expression
multiple interactions
ISO linsidomine results in increased expression of PRKN protein
Selegiline inhibits the reaction [linsidomine results in increased expression of PRKN protein]
CTD PMID:12880480 NCBI chr 1:48,880,015...50,069,998 JBrowse link
G Pten phosphatase and tensin homolog increases oxidation EXP linsidomine results in increased oxidation of PTEN protein CTD PMID:17302912 NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
JBrowse link
G Rab29 RAB29, member RAS oncogene family increases oxidation EXP linsidomine results in increased oxidation of RAB29 protein CTD PMID:28086193 NCBI chr13:48,644,575...48,650,229
Ensembl chr13:48,644,604...48,650,220
JBrowse link
G Ran RAN, member RAS oncogene family increases oxidation EXP linsidomine results in increased oxidation of RAN protein CTD PMID:28086193 NCBI chr12:31,319,556...31,324,105
Ensembl chr12:31,320,624...31,323,810
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases phosphorylation ISO linsidomine results in decreased phosphorylation of RB1 protein CTD PMID:12600834 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [linsidomine affects the activity of RELA protein]; linsidomine affects the localization of and affects the activity of RELA protein CTD PMID:29175419 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rexo5 RNA exonuclease 5 increases oxidation EXP linsidomine results in increased oxidation of REXO5 protein CTD PMID:28086193 NCBI chr 1:189,549,960...189,643,698
Ensembl chr 1:189,549,960...189,622,094
JBrowse link
G Ryr2 ryanodine receptor 2 increases oxidation EXP linsidomine results in increased oxidation of RYR2 protein CTD PMID:28086193 NCBI chr17:65,533,998...65,955,606
Ensembl chr17:65,535,403...65,955,606
JBrowse link
G Sclt1 sodium channel and clathrin linker 1 increases oxidation EXP linsidomine results in increased oxidation of SCLT1 protein CTD PMID:28086193 NCBI chr 2:128,523,376...128,675,668
Ensembl chr 2:128,523,636...128,675,408
JBrowse link
G Scn8a sodium voltage-gated channel alpha subunit 8 increases oxidation EXP linsidomine results in increased oxidation of SCN8A protein CTD PMID:28086193 NCBI chr 7:142,575,629...142,683,659
Ensembl chr 7:142,575,672...142,684,114
JBrowse link
G Secisbp2 SECIS binding protein 2 increases oxidation EXP linsidomine results in increased oxidation of SECISBP2 protein CTD PMID:28086193 NCBI chr17:13,555,348...13,586,595
Ensembl chr17:13,555,349...13,586,554
JBrowse link
G Sfrp4 secreted frizzled-related protein 4 increases oxidation EXP linsidomine results in increased oxidation of SFRP4 protein CTD PMID:28086193 NCBI chr17:47,383,983...47,394,065
Ensembl chr17:47,297,489...47,394,328
JBrowse link
G Slc12a2 solute carrier family 12 member 2 multiple interactions
increases activity
EXP linsidomine results in increased phosphorylation of and results in increased expression of SLC12A2 protein
linsidomine results in increased activity of SLC12A2 protein
CTD PMID:25817889 NCBI chr18:52,917,124...52,985,281
Ensembl chr18:52,917,124...52,985,261
JBrowse link
G Smc1a structural maintenance of chromosomes 1A increases oxidation EXP linsidomine results in increased oxidation of SMC1A protein CTD PMID:28086193 NCBI chr  X:21,710,976...21,755,708
Ensembl chr  X:21,711,019...21,755,525
JBrowse link
G Snca synuclein alpha increases expression
multiple interactions
ISO linsidomine results in increased expression of SNCA protein
Selegiline inhibits the reaction [linsidomine results in increased expression of SNCA protein]
CTD PMID:12880480 NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO linsidomine results in decreased activity of and results in decreased expression of SOD1 protein; Plant Extracts inhibits the reaction [linsidomine results in decreased activity of and results in decreased expression of SOD1 protein] CTD PMID:23174672 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases response to substance
increases expression
ISO Acetylcysteine inhibits the reaction [linsidomine results in increased expression of SOD2 mRNA]; Cysteine inhibits the reaction [linsidomine results in increased expression of SOD2 mRNA]
SOD2 protein results in increased susceptibility to linsidomine
CTD PMID:9741582, PMID:10511315 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Speg striated muscle enriched protein kinase increases oxidation EXP linsidomine results in increased oxidation of SPEG protein CTD PMID:28086193 NCBI chr 9:82,571,333...82,628,684
Ensembl chr 9:82,571,269...82,628,709
JBrowse link
G Svep1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 increases oxidation EXP linsidomine results in increased oxidation of SVEP1 protein CTD PMID:28086193 NCBI chr 5:75,147,245...75,320,873
Ensembl chr 5:75,143,867...75,319,765
JBrowse link
G Synrg synergin, gamma increases oxidation EXP linsidomine results in increased oxidation of SYNRG protein CTD PMID:28086193 NCBI chr10:71,278,698...71,357,791 JBrowse link
G Sytl4 synaptotagmin-like 4 increases oxidation EXP linsidomine results in increased oxidation of SYTL4 protein CTD PMID:28086193 NCBI chr  X:104,763,961...104,814,152
Ensembl chr  X:104,765,294...104,814,145
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases activity
decreases expression
EXP 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide inhibits the reaction [linsidomine results in decreased expression of TGFB1 mRNA]; 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide inhibits the reaction [linsidomine results in decreased expression of TGFB1 protein]
linsidomine results in increased activity of TGFB1 protein
linsidomine results in decreased expression of TGFB1 mRNA; linsidomine results in decreased expression of TGFB1 protein
CTD PMID:11994256 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO TLR4 gene mutant form inhibits the reaction [linsidomine results in increased secretion of IL6 protein]; TLR4 gene mutant form inhibits the reaction [linsidomine results in increased secretion of TNF protein] CTD PMID:29175419 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
G Tnf tumor necrosis factor increases secretion
multiple interactions
ISO linsidomine results in increased secretion of TNF protein
TLR4 gene mutant form inhibits the reaction [linsidomine results in increased secretion of TNF protein]
CTD PMID:29175419 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Trim40 tripartite motif-containing 40 increases oxidation EXP linsidomine results in increased oxidation of TRIM40 protein CTD PMID:28086193 NCBI chr20:2,169,674...2,178,477
Ensembl chr20:2,169,545...2,178,601
JBrowse link
G Trpm1 transient receptor potential cation channel, subfamily M, member 1 increases oxidation EXP linsidomine results in increased oxidation of TRPM1 protein CTD PMID:28086193 NCBI chr 1:124,983,391...125,101,759
Ensembl chr 1:124,983,452...125,099,573
JBrowse link
G Trpm7 transient receptor potential cation channel, subfamily M, member 7 increases oxidation EXP linsidomine results in increased oxidation of TRPM7 protein CTD PMID:28086193 NCBI chr 3:119,258,189...119,347,084
Ensembl chr 3:119,259,467...119,330,345
JBrowse link
G Unc13a unc-13 homolog A increases oxidation EXP linsidomine results in increased oxidation of UNC13A protein CTD PMID:28086193 NCBI chr16:20,056,398...20,103,951
Ensembl chr16:20,056,765...20,097,287
JBrowse link
G Vgf VGF nerve growth factor inducible increases oxidation EXP linsidomine results in increased oxidation of VGF protein CTD PMID:28086193 NCBI chr12:22,677,302...22,680,630
Ensembl chr12:22,677,607...22,680,630
JBrowse link
G Vim vimentin increases oxidation EXP linsidomine results in increased oxidation of VIM protein CTD PMID:28086193 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Wdr7 WD repeat domain 7 increases oxidation EXP linsidomine results in increased oxidation of WDR7 protein CTD PMID:28086193 NCBI chr18:59,096,636...59,396,312
Ensembl chr18:59,096,643...59,396,318
JBrowse link
G Whrn whirlin increases oxidation EXP linsidomine results in increased oxidation of WHRN protein CTD PMID:28086193 NCBI chr 5:79,235,541...79,317,206
Ensembl chr 5:79,234,950...79,317,206
JBrowse link
G Ythdc1 YTH domain containing 1 increases oxidation EXP linsidomine results in increased oxidation of YTHDC1 protein CTD PMID:28086193 NCBI chr14:22,971,834...23,002,326
Ensembl chr14:22,971,836...23,002,011
JBrowse link
G Zfp148 zinc finger protein 148 increases oxidation EXP linsidomine results in increased oxidation of ZFP148 protein CTD PMID:28086193 NCBI chr11:70,509,909...70,618,422
Ensembl chr11:70,514,750...70,618,347
JBrowse link
G Zfp518a zinc finger protein 518A increases oxidation EXP linsidomine results in increased oxidation of ZFP518A protein CTD PMID:28086193 NCBI chr 1:260,152,881...260,178,360
Ensembl chr 1:260,153,645...260,178,349
JBrowse link
LY294002 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A decreases expression ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1 mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1 protein CTD PMID:23466342, PMID:27888070 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B multiple interactions
decreases expression
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[NFKB1 protein binds to RELA protein] which results in increased expression of ABCB1B mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Curcumin results in decreased expression of ABCB1B protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1B protein
CTD PMID:18006147 NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCC1 protein CTD PMID:27888070 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [erucin results in increased expression of ABCC2 mRNA] CTD PMID:15896333 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc5 ATP binding cassette subfamily C member 5 decreases expression ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCC5 protein CTD PMID:23994249 NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 protein] CTD PMID:21712253 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] CTD PMID:16849647 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acvr2b activin A receptor type 2B multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of ACVR2B mRNA] CTD PMID:12710931 NCBI chr 8:128,087,308...128,126,776
Ensembl chr 8:128,087,345...128,118,746
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of NOS3 protein] CTD PMID:19356108 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Adra1a adrenoceptor alpha 1A multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose] CTD PMID:15550506 NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
JBrowse link
G Ager advanced glycosylation end product-specific receptor multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vitamin A results in increased expression of AGER protein] CTD PMID:21807062 NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
JBrowse link
G Agt angiotensinogen multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein results in increased expression of POSTN mRNA] CTD PMID:15121739, PMID:16325820, PMID:23300732, PMID:25398788 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Ahr aryl hydrocarbon receptor increases expression
multiple interactions
decreases expression
EXP
ISO
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AHR mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AHR protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TGFB1 protein results in increased activity of AHR protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AHR mRNA
CTD PMID:22406437, PMID:27020609 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] CTD PMID:17640564 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 decreases expression ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKR1B10 protein CTD PMID:23994249 NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein] CTD PMID:21787718 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases expression
decreases phosphorylation
multiple interactions
decreases expression
decreases activity
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltiprotoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [LEPR gene mutant form results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Mercuric Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Methylmercury Compounds results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Phospholipids results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [Okadaic Acid results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [RELN protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tretinoin results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased activity of and results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with HRAS protein] results in decreased phosphorylation of AKT1 protein; [Butyrates co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKT1 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the localization of [PDK1 protein binds to AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-hydroxyestradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in decreased degradation of NOS3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[FGF7 protein results in increased phosphorylation of AKT1 protein] which results in increased expression of ESR1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[HSPA1A protein co-treated with Formaldehyde] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[MIR21 mRNA results in decreased susceptibility to Cisplatin] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Rosiglitazone co-treated with IAPP protein] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acetylcysteine results in increased activity of and results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Atrazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased cleavage of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Caffeine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cotinine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [DEFA1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [DEFA2 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Diethylhexyl Phthalate results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Diethylhexyl Phthalate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dronabinol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Furazolidone results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [GW0742 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [hemistepsin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS protein results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [KMUP 1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [methanandamide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NLRC5 protein results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NLRC5 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Phosphates results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Polychlorinated Biphenyls analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [propazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [PTK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [stearic acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [terbutylazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Thapsigargin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [titanium dioxide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vehicle Emissions results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Arsenic Trioxide results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [di-n-propyldithiocarbamate results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [kahweol results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Oligopeptides analog results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [polyphenon E results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [pristimerin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of and results in decreased phosphorylation of AKT1 protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of and results in decreased activity of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Benzo(a)pyrene] results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Quercetin] inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Quercetin] results in decreased phosphorylation of AKT1 protein; [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Formaldehyde co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [PDK1 protein binds to AKT1 protein] inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; [PDK1 protein binds to AKT1 protein] inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of RPS6 protein]; [PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [sodium arsenite co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; Arsenic Trioxide promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Cisplatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; kahweol promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; polyphenon E promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Tamoxifen promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased activity of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[5-aminoisoquinolinone co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Capsaicin co-treated with Oxygen deficiency co-treated with Oxygen] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cilomilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Doxepin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased activity of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Epirubicin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [GRN protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Isoproterenol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [LHCGR protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Mevinphos results in increased activity of and results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [MT2A protein inhibits the reaction [Tunicamycin results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NGF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rhodioloside inhibits the reaction [Colistin results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sevoflurane results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Thapsigargin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tunicamycin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vitamin A results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Tunicamycin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of and results in decreased activity of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tretinoin] results in decreased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKT1 protein
CTD PMID:11306697, PMID:11788791, PMID:12438947, PMID:12511591, PMID:12556562, PMID:12640124, PMID:12710931, PMID:12821261, PMID:12834810, PMID:14755253, PMID:14757120, PMID:14762343, PMID:15001399, PMID:15028728, PMID:15050414, PMID:15177934, PMID:15178407, PMID:15213310, PMID:15339911, PMID:15631803, PMID:15695173, PMID:15845746, PMID:15897870, PMID:15919668, PMID:15956784, PMID:16018989, PMID:16059913, PMID:16168102, PMID:16179367, PMID:16204373, PMID:16211241, PMID:16256798, PMID:16275998, PMID:16288212, PMID:16343977, PMID:16434995, PMID:16472761, PMID:16619521, PMID:16648635, PMID:16682453, PMID:16731823, PMID:16763222, PMID:16973122, PMID:17172471, PMID:17259349, PMID:17324588, PMID:17346750, PMID:17464197, PMID:17513037, PMID:17550345, PMID:17583570, PMID:17623046, PMID:17823925, PMID:17922026, PMID:17962351, PMID:18096819, PMID:18201823, PMID:18276108, PMID:18359480, PMID:18388193, PMID:18622747, PMID:18948619, PMID:19011674, PMID:19038232, PMID:19059400, PMID:19073151, PMID:19139269, PMID:19176369, PMID:19233221, PMID:19299917, PMID:19356108, PMID:19457607, PMID:19561517, PMID:19661335, PMID:19781563, PMID:19814765, PMID:19881297, PMID:19906781, PMID:19956873, PMID:19962417, PMID:20361045, PMID:20386985, PMID:20464445, PMID:20562903, PMID:20600219, PMID:20610540, PMID:20657188, PMID:20658310, PMID:20938987, PMID:21055460, PMID:21138475, PMID:21474332, PMID:21594580, PMID:21655183, PMID:21803128, PMID:21807062, PMID:21820214, PMID:21821001, PMID:21837363, PMID:21976531, PMID:22019741, PMID:22040890, PMID:22046442, PMID:22545124, PMID:22556157, PMID:22687995, PMID:23000059, PMID:23159718, PMID:23285096, PMID:23300809, PMID:23352507, PMID:23453443, PMID:23466500, PMID:23735482, PMID:23793038, PMID:23880231, PMID:23958495, PMID:24057571, PMID:24122885, PMID:24361488, PMID:24449419, PMID:24462917, PMID:24680926, PMID:24727557, PMID:24875536, PMID:24876378, PMID:24898257, PMID:24946264, PMID:25118938, PMID:25171655, PMID:25203460, PMID:25303017, PMID:25398788, PMID:25471227, PMID:25597859, PMID:25644787, PMID:25773745, PMID:25866362, PMID:26048653, PMID:26089345, PMID:26282490, PMID:26364587, PMID:26506538, PMID:26687534, PMID:26790143, PMID:26942697, PMID:26974319, PMID:27049278, PMID:27050422, PMID:27295300, PMID:27312872, PMID:27338800, PMID:27431321, PMID:27542212, PMID:27658547, PMID:28302560, PMID:28465020, PMID:28756148, PMID:28940008, PMID:29061316, PMID:29186614, PMID:29505745, PMID:29510123, PMID:30205135, PMID:30600586, PMID:30726812, PMID:30851366, PMID:31068539, PMID:31445927, PMID:31715269, PMID:31743544, PMID:31830547, PMID:32602595, PMID:32613688, PMID:32687844 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Akt1s1 AKT1 substrate 1 decreases phosphorylation EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1S1 protein CTD PMID:17457363 NCBI chr 1:100,845,443...100,851,961
Ensembl chr 1:100,845,563...100,851,960
JBrowse link
G Angpt1 angiopoietin 1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein results in decreased susceptibility to Doxorubicin] CTD PMID:15763944 NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
JBrowse link
G Angpt2 angiopoietin 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in increased expression of MKI67 protein] CTD PMID:31838054 NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
JBrowse link
G Apln apelin increases expression
multiple interactions
increases secretion
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of APLN mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Eicosapentaenoic Acid results in increased expression of APLN mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased secretion of APLN protein
CTD PMID:20352620, PMID:21461750 NCBI chr  X:134,856,719...134,866,210
Ensembl chr  X:134,856,726...134,866,210
JBrowse link
G App amyloid beta precursor protein multiple interactions ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in decreased expression of APP protein alternative form]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [coenzyme Q10 results in decreased susceptibility to APP protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in increased activity of CASP3 protein]
CTD PMID:16648635, PMID:19741129, PMID:22186599, PMID:28756148 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in increased expression of AQP3 protein] CTD PMID:16848764, PMID:18214481 NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
JBrowse link
G Aqp9 aquaporin 9 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dihydrotestosterone results in decreased expression of AQP9 mRNA] CTD PMID:20378617 NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
JBrowse link
G Ar androgen receptor multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased expression of AR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in decreased expression of AR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [methoxyacetic acid promotes the reaction [Testosterone results in increased activity of AR protein]] CTD PMID:16472761, PMID:18486176, PMID:19059400 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Arg2 arginase 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased expression of ARG2 protein] CTD PMID:24951775 NCBI chr 6:102,311,097...102,338,406
Ensembl chr 6:102,311,116...102,338,520
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]; Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]]; SB 216763 inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]] CTD PMID:24057571 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO
EXP
[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with HRAS protein] results in decreased expression of ATF6 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Cadmium Chloride results in increased expression of ATF6 protein]]
CTD PMID:24898257, PMID:31433112 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Genistein results in increased phosphorylation of ATM protein] CTD PMID:19038232 NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
JBrowse link
G Aurkb aurora kinase B decreases expression ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AURKB protein CTD PMID:21530604 NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions
decreases phosphorylation
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acrolein results in increased phosphorylation of BAD protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in decreased activity of BAD protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [polyphenon E results in decreased phosphorylation of BAD protein]; polyphenon E promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of BAD protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rottlerin inhibits the reaction [trimethyltin results in decreased expression of BAD protein modified form]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]
CTD PMID:12438947, PMID:12970779, PMID:14628071, PMID:17123556, PMID:17559149, PMID:19596284, PMID:23285096, PMID:25895139 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects localization
increases expression
multiple interactions
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the localization of BAX protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BAX protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rottlerin inhibits the reaction [trimethyltin results in increased expression of BAX protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rhodioloside inhibits the reaction [Colistin results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [Emodin affects the expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [delphinidin promotes the reaction [TGFB1 results in decreased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rebamipide results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Nitroprusside affects the localization of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Stilbenes analog affects the localization of BAX protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with TNFSF10 protein] results in increased activity of BAX protein; [Arsenic Trioxide co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased activity of BAX protein; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]]
CTD PMID:15665116, PMID:15942663, PMID:18449500, PMID:20097879, PMID:20386985, PMID:20856197, PMID:22178905, PMID:23201927, PMID:25895139, PMID:27032576, PMID:28465020, PMID:29054700, PMID:29186614, PMID:30365941, PMID:31433112, PMID:31838054, PMID:32602595 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression
ISO
EXP
[Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased expression of BBC3 protein; TP53 protein promotes the reaction [[Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased expression of BBC3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BBC3 protein
CTD PMID:20856197, PMID:24567336 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
increases expression
increases phosphorylation
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [Emodin affects the expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [delphinidin inhibits the reaction [TGFB1 results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rebamipide results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2 mRNA; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of and results in increased localization of BID protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]]; BCL2 protein results in decreased susceptibility to [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BCL2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [5-aminoisoquinolinone inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in decreased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rhodioloside inhibits the reaction [Colistin results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium bisulfide results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rottlerin inhibits the reaction [trimethyltin results in decreased expression of BCL2 protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased phosphorylation of BCL2 protein
CTD PMID:16018989, PMID:20386985, PMID:20856197, PMID:21130731, PMID:21800153, PMID:21803128, PMID:22046442, PMID:23201927, PMID:23352507, PMID:25895139, PMID:25955216, PMID:27032576, PMID:28185818, PMID:28465020, PMID:29054700, PMID:29186614, PMID:30365941, PMID:31433112, PMID:31838054, PMID:32602595 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Butyrates results in increased expression of BCL2A1 mRNA] CTD PMID:16256798 NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
increases degradation
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rebamipide results in increased expression of BCL2L1 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2L1 mRNA; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2L1 protein; LGALS3 inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased degradation of BCL2L1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B inhibits the reaction [arsenic trioxide results in decreased expression of BCL2L1 protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BCL2L1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rottlerin inhibits the reaction [trimethyltin results in decreased expression of BCL2L1 protein]]
CTD PMID:14762343, PMID:18789402, PMID:21173233, PMID:21821001, PMID:22046442, PMID:23201927, PMID:25895139, PMID:29054700 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rebamipide results in decreased expression of BCL2L11 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Doxorubicin] results in decreased phosphorylation of BCL2L11 protein; Resveratrol promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2L11 protein alternative form]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]]
CTD PMID:20856197, PMID:21179458, PMID:25471227, PMID:29054700 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] CTD PMID:16849647 NCBI chr20:14,421,250...14,546,406
Ensembl chr20:14,421,141...14,545,772
JBrowse link
G Bdkrb1 bradykinin receptor B1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IL1A protein results in increased expression of BDKRB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of BDKRB1 protein] CTD PMID:29775649 NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased chemical synthesis of Nitric Oxide]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased phosphorylation of CREB1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein]
CTD PMID:17172126, PMID:17209049, PMID:19962417, PMID:29061316 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Becn1 beclin 1 multiple interactions
increases expression
EXP
ISO
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in increased expression of BECN1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Benzo(a)pyrene results in increased expression of BECN1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BECN1 protein
CTD PMID:25955216, PMID:30726812 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of and results in increased localization of BID protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Emodin results in increased degradation of BID protein]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of and results in increased localization of BID protein]] CTD PMID:20856197, PMID:27032576 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 multiple interactions
decreases expression
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acrolein results in increased expression of BIRC2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC2 mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Butyrates results in increased expression of BIRC2 mRNA]
CTD PMID:12970779, PMID:14762343, PMID:15065019, PMID:16256798, PMID:19596284 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 multiple interactions
decreases expression
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acrolein results in increased expression of BIRC3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Thapsigargin results in increased expression of BIRC3 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Thapsigargin results in increased expression of BIRC3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC3 protein
CTD PMID:12970779, PMID:14762343, PMID:15339911, PMID:19596284 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
increases expression
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CALCA protein results in increased expression of BIRC5 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [arsenic trioxide results in decreased expression of BIRC5 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased expression of BIRC5 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BIRC5 mRNA; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BIRC5 protein; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BIRC5 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cisplatin results in increased expression of BIRC5 mRNA]
CTD PMID:15065019, PMID:16222118, PMID:17472962, PMID:17548900, PMID:18606715, PMID:19211844, PMID:20464445, PMID:20514400, PMID:21594580, PMID:22046442 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [FOS protein binds to BMP2 promoter]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [JUN protein binds to BMP2 promoter]] CTD PMID:18495116 NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
JBrowse link
G Btc betacellulin multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BTC protein results in increased expression of CCND1 protein] CTD PMID:19105244 NCBI chr14:18,231,854...18,270,621
Ensembl chr14:18,231,860...18,272,484
JBrowse link
G Ca9 carbonic anhydrase 9 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltous chloride results in increased expression of CA9 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased expression of CA9 protein]; PTEN protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltous chloride results in increased expression of CA9 protein]]; PTEN protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased expression of CA9 protein]] CTD PMID:19808899 NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CALCA protein results in decreased susceptibility to Etoposide]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CALCA protein results in increased expression of BIRC5 protein] CTD PMID:16222118 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
JBrowse link
G Camp cathelicidin antimicrobial peptide multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol promotes the reaction [Resveratrol results in increased expression of CAMP mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol results in increased expression of CAMP mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol promotes the reaction [Calcitriol results in increased expression of CAMP mRNA]] CTD PMID:24039193 NCBI chr 8:117,930,557...117,932,371
Ensembl chr 8:117,930,546...117,932,518
JBrowse link
G Casp1 caspase 1 multiple interactions
increases cleavage
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Toluene 2,4-Diisocyanate results in increased cleavage of CASP1 protein]
[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Benzo(a)pyrene] results in increased cleavage of CASP1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased cleavage of CASP1 protein
CTD PMID:25929181, PMID:30726812 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
JBrowse link
G Casp2 caspase 2 multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in increased activity of CASP2 protein]] CTD PMID:19801490 NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased cleavage of CASP3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [5-aminoisoquinolinone inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in decreased expression of CASP3 protein modified form]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rhodioloside inhibits the reaction [Colistin results in increased activity of and results in increased cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B inhibits the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in increased activity of CASP3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [Indomethacin results in increased activity of CASP3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [delphinidin inhibits the reaction [TGFB1 results in increased expression of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [fenvalerate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Paraquat results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased activity of and results in increased localization of CASP3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Emodin results in increased cleavage of CASP3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Resveratrol results in increased activity of CASP3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased cleavage of and results in increased activity of CASP3 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with fludarabine] results in increased cleavage of CASP3 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with gemcitabine] affects the activity of CASP3 protein; [TNFSF10 protein co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased cleavage of CASP3 protein; [U 0126 co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [fenvalerate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; Boc-D-FMK inhibits the reaction [[fludarabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased cleavage of CASP3 protein]; MAP2K1 protein inhibits the reaction [[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with fludarabine] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fludarabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased cleavage of CASP3 protein]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased activity of CASP3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cadmium sulfate results in increased activity of CASP3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rottlerin inhibits the reaction [trimethyltin results in increased expression of CASP3 protein modified form]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; [Butyrates co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased activity of CASP3 protein
CTD PMID:14687664, PMID:14688022, PMID:15695173, PMID:15850772, PMID:15942663, PMID:16018989, PMID:16256798, PMID:16275998, PMID:16487511, PMID:17045724, PMID:17341418, PMID:17928571, PMID:19233221, PMID:19261616, PMID:19738051, PMID:19801490, PMID:19827268, PMID:20856197, PMID:23143138, PMID:23201927, PMID:23300732, PMID:23352507, PMID:23419388, PMID:24602480, PMID:25773745, PMID:25895139, PMID:26686574, PMID:27032576, PMID:28025122, PMID:28185818, PMID:28465020, PMID:28756148, PMID:28949029, PMID:29782821, PMID:30365941, PMID:31433112, PMID:31935362 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp4 caspase 4 multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in increased activity of CASP5 protein]] CTD PMID:19801490 NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
JBrowse link
G Casp6 caspase 6 multiple interactions EXP
ISO
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in increased activity of CASP6 protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [Indomethacin results in increased activity of CASP6 protein]
CTD PMID:17341418, PMID:19801490 NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967
Ensembl chr 2:235,341,365...235,353,967
JBrowse link
G Casp7 caspase 7 increases activity
increases cleavage
multiple interactions
EXP
ISO
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased activity of CASP7 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased cleavage of CASP7 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cadmium sulfate results in increased activity of CASP7 protein]
CTD PMID:14687664, PMID:14688022, PMID:16487511 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions
increases activity
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Emodin results in increased activity of CASP8 protein]; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased activity of CASP8 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with fludarabine] results in increased cleavage of CASP8 protein; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]] CTD PMID:15850772, PMID:15942663, PMID:20856197, PMID:27032576 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [Indomethacin results in increased activity of CASP9 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Pyruvaldehyde results in increased expression of CASP9 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased activity of CASP9 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with fludarabine] results in increased cleavage of CASP9 protein; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased cleavage of CASP9 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein]]
CTD PMID:12438947, PMID:15850772, PMID:16412023, PMID:17341418, PMID:19801490, PMID:20856197, PMID:26577515 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in decreased expression of CAT protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein]] CTD PMID:22040890, PMID:32602595 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccl11 C-C motif chemokine ligand 11 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CCL11 protein results in increased expression of ITGAM protein] CTD PMID:11980903 NCBI chr10:69,434,965...69,439,566
Ensembl chr10:69,434,941...69,439,575
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Digitoxin inhibits the reaction [IL1B protein results in increased expression of CCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TNF protein results in increased expression of CCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lead acetate results in increased secretion of CCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with U 0126] inhibits the reaction [lead acetate results in increased secretion of CCL2 protein]
CTD PMID:16794257, PMID:19293636, PMID:19446813, PMID:20354174, PMID:22225513, PMID:24530660, PMID:25171655 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA] CTD PMID:22225513 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccn1 cellular communication network factor 1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acetylcysteine results in increased expression of CCN1 protein] CTD PMID:21055460 NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein] CTD PMID:26054450 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccna2 cyclin A2 decreases expression
multiple interactions
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CCNA2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vanadates results in increased expression of CCNA2 protein]
CTD PMID:14971663, PMID:17148679 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased expression of CCND1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sirolimus results in increased expression of CCND1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CCND1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [leptin (116-130) results in decreased expression of CCND1 mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CCND1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BTC protein results in increased expression of CCND1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CCND1 protein]
CTD PMID:14750165, PMID:14757120, PMID:15695173, PMID:16412023, PMID:17148679, PMID:19105244, PMID:19661225, PMID:21179458, PMID:24231000, PMID:27312872, PMID:31499123 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 multiple interactions
decreases expression
decreases methylation
increases expression
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CCND2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased methylation of CCND2 promoter
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of CCND2 mRNA
CTD PMID:14745455, PMID:15601625, PMID:15778701 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccnd3 cyclin D3 multiple interactions
decreases expression
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CCND3 protein
CTD PMID:14757120, PMID:15601625, PMID:15778701 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Ccne1 cyclin E1 multiple interactions
decreases expression
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vanadates results in increased expression of CCNE1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CCNE1 protein
CTD PMID:14757120, PMID:14971663, PMID:15601625 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Silicon Dioxide results in increased expression of CCR2 protein] CTD PMID:26163174
G Cd274 CD274 molecule decreases expression
multiple interactions
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CD274 mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CD274 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [nano-diamino-tetrac results in decreased expression of CD274 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [nano-diamino-tetrac results in decreased expression of CD274 protein]; nano-diamino-tetrac promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of CD274 protein]
CTD PMID:29960019 NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943
JBrowse link
G Cd36 CD36 molecule multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CD36 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased expression of CD36 mRNA] CTD PMID:19640849, PMID:25712622 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TNF protein results in increased activity of CD38 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TNF protein results in increased expression of CD38 mRNA] CTD PMID:22556157 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of CDH1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in decreased expression of CDH1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in decreased expression of CDH1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in decreased expression of CDH1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of CDH1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Toluene 2,4-Diisocyanate affects the localization of CDH1 protein]
CTD PMID:23921149, PMID:25118938, PMID:25656647, PMID:26089345, PMID:26363213, PMID:27856280 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased expression of CDH2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of CDH2 protein] CTD PMID:24997338 NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
JBrowse link
G Cdk16 cyclin-dependent kinase 16 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of CDK16 mRNA] CTD PMID:12710931 NCBI chr  X:1,707,285...1,718,821
Ensembl chr  X:1,707,289...1,718,637
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CDK4 protein] CTD PMID:27312872 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of CDKN1A protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Dexamethasone results in decreased expression of and affects the localization of CDKN1A protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Dexamethasone results in decreased stability of CDKN1A protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CDKN1A protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Resveratrol co-treated with Clofarabine] results in decreased expression of CDKN1A protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [leptin (116-130) results in increased expression of CDKN1A mRNA]
CTD PMID:15001399, PMID:15695173, PMID:17148679, PMID:23146690, PMID:25791921, PMID:26687534, PMID:27312872, PMID:28940008, PMID:31499123 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression
ISO [decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of CDKN1B mRNA; [resveratrol co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased expression of CDKN1B protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of CDKN1B protein
CTD PMID:11322924, PMID:15601625, PMID:17148679, PMID:18622747, PMID:21179458 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of CDKN2A mRNA] CTD PMID:12710931 NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
JBrowse link
G Cdx2 caudal type homeo box 2 multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CDX2 protein results in increased expression of IL1B mRNA] CTD PMID:15350541 NCBI chr12:9,464,026...9,470,565
Ensembl chr12:9,464,026...9,470,565
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of CEBPA mRNA] CTD PMID:25712622 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CEBPB mRNA] CTD PMID:25712622 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CFLAR protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CFLAR protein alternative form CTD PMID:12970779, PMID:16434995, PMID:21173233 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein] CTD PMID:15563584 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
JBrowse link
G Chrna7 cholinergic receptor nicotinic alpha 7 subunit multiple interactions ISO 2-(4-